

STIC Database Tracking Number: 317604

**To: Examiner Mark Fleischer**  
**Location: KNX5B16**  
**Art Unit: 3624**  
**Date: 12/17/2009**  
**Case Serial Number: 10/693790**

**From: Matthew Hogan**  
**Location: EIC3600**  
**KNX 2D08B**  
**Phone: (571) 272-6674**  
**Matthew.Hogan@uspto.gov**

## Search Notes

Dear Examiner FLEISCHER:

Please find attached the results of your requested search related to the above-referenced case. The search was conducted in Dialog, EBSCOhost (I & PC Abs.), STN MechEng, and ProQuest (Fin. Times),

I have suggested *potential* references of interest in the first part of the search results. However, please be sure to review the entire report. There may be additional references that you find useful.

Please note that the results, after the potential references of interest, proceed through an Inventor search (which is provided without regard to priority date and in GREEN TEXT) and then to results in both Abstract and Full Text databases (which are more directly screened for priority date).

If you have any questions about the search, or need a refocus, please do not hesitate to contact me.

Thank you for using the EIC, and we look forward to your next search!

I.	POTENTIAL REFERENCES OF INTEREST .....	3
II.	INVENTOR SEARCH .....	8
A.	Dialog .....	8
III.	TEXT SEARCH RESULTS FROM DIALOG (FULL TEXT DBS) .....	18
IV.	TEXT SEARCH RESULTS FROM DIALOG (ABSTRACT DBS).....	36
A.	Abstract Databases -- Patent.....	36
V.	ADDITIONAL RESOURCES SEARCHED .....	71

## I. Potential References of Interest

*\* EIC-Searcher identified "potential references of interest" are selected based on the terms/concepts provided in the examiner's search request.*

12/3,K/34 (Item 2 from file: 444)  
DIALOG(R)File 444: New England Journal of Med.  
(c) 2009 Mass. Med. Soc. All rights reserved.  
00102941  
Copyright 1987 by the Massachusetts Medical Society

### **Decreasing Risk Of Leukemia With Prolonged Follow-up After Chemotherapy And Radiotherapy For Hodgkin's Disease (Original Article)**

Blayney, Douglas W.; Longo, Dan L.; Young, Robert C.; Greene, Mark H.; Hubbard, Susan M., R.N.; Postal, Marcia G., R.N., M.S.; Duffey, Patricia L., R.N.; DeVita, Vincent T., Jr.  
The New England Journal of Medicine  
March 19 , 1987 ; 316 (12),pp 710-714  
**Line Count:** 00336      **Word Count:** 04639

#### **Text:**

...events occurred at the same time after the start of observation. An estimated risk function was computed, expressing the risk of an event per total **person-years** of **observation** during each interval. The estimated **value** of the **risk** function was used in a multiple linear regression analysis. The natural logarithm of the estimated risk was selected as the dependent variable, and time and...

14/3,K/4 (Item 1 from file: 148)  
DIALOG(R)File 148: Gale Group Trade & Industry DB  
(c) 2009 Gale/Cengage. All rights reserved.

15979263      **Supplier Number:** 103731431 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Length of stay, conditional length of stay, and prolonged stay in pediatric asthma. (Access in Chronic Care).(a study finds the overall management of asthma admissions appears more efficient in Pennsylvania than in New York)(Illustration)**

Silber, Jeffrey H.; Rosenbaum, Paul R.; Even-Shoshan, Orit; Shabbout, Mayadah; Zhang, Xuemei; Bradlow, Eric T.; Marsh, Roger R.  
Health Services Research , 38 , 3 , 867(20)  
June , 2003

**Document Type:** Illustration

ISSN: 0017-9124

**Language:** English

**Record Type:** Fulltext; Abstract

**Word Count:** 7080      **Line Count:** 00725

...stay" (CLOS)) (Silber et al. 1999b), this report aims to provide insight

into state, city, and hospital differences in the patterns of stay for asthma **patients**. Through this approach, we aim to aid policymakers to better understand some potential etiologies for these differences, so that future policy initiatives can better focus on likely avenues for **successful interventions**.

#### METHODS

##### **Patient Population**

We obtained claims data on all pediatric admissions ages 1-17 in Pennsylvania for the period 1/1/96-12/31/98 and in New York State for the period 1/1/96-9/30/98. **Patients** admitted to psychiatric and nonacute care hospitals were not included in this study. Data from Pennsylvania were provided through the Pennsylvania Health Care Cost Containment...

9/5,K/14 (Item 10 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2009 The Thomson Corporation. All rights reserved.

14522954 **Biosis No.:** 199800317201

#### **Evaluation of mortality factors and risk analysis for the design of an integrated pest management system**

**Author:** Roux Olivier (Reprint); Baumgartner Johann

**Author Address:** Swiss Federal Office Agriculture, Mattenhofstr. 5, CH-3003 Bern, Switzerland\*\*Switzerland

**Journal:** Ecological Modelling 109 ( 1 ): p 61-75 June 1, 1998 1998

**Medium:** print

**ISSN:** 0304-3800

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** A probabilistic approach of survival analysis based on the theory of competing risks was applied to the potato tuber moth *Phthorimaea operculella* (Zeller) affecting tubers in Tunisian rustic stores. Exponential curve of death. i.e., constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors. which permits to judge different control strategies. In an integrated pest management perspective, the effect of basic mortalities, i.e., innate and dispersal related mortalities is recombined with native natural enemies. Thereafter, we calculate the force of additional compatible control factors needed to reduce the proportion of infested tubers below an economically relevant level. Control strategies based on native natural enemies are shown to have variable effects which put farmers at economic risks. The general importance of integrating compatible control factors is recognized in the evaluation of virus applications. Based on risk analyses. Tunisian potato growers were recommended, in the case of standard initial infestations of five eggs per tuber,

to use virus preparations at a higher dosage than the 0.0015 larval equivalent kg as used in this study. Moreover, the study confirms the general importance of entering potatoes with low infestation levels into rustic shelters. This considerably decreases the risk of exceeding the economic threshold and make virus based control efficient even at low dosages. If the initial infestation considerably exceeds five eggs per tuber, the integration of a compatible control factor becomes more difficult. Nevertheless, even in absence of additional control factors the infestation of tubers does not exceed 50%.

#### **DESCRIPTORS:**

**Major Concepts:** Mathematical Biology--Computational Biology; Pest Assessment Control and Management

**Biosystematic Names:** Lepidoptera--Insecta, Arthropoda, Invertebrata, Animalia; Solanaceae-- Dicotyledones, Angiospermae, Spermatophyta, Plantae

**Organisms:** Phthorimaea operculella {potato tuber moth} (Lepidoptera)--storage pest; potato

**Common Taxonomic Terms:** Animals; Arthropods; Insects; Invertebrates; Angiosperms; Dicots; Plants; Spermatophytes; Vascular Plants

**Geographical Name:** Tunisia (Palearctic region)

**Miscellaneous Terms: Concept Codes:** competing risks; economics; hazard rate functions; integrated pest management; mortality factors; survival analysis

#### **Concept Codes:**

60015 Economic entomology - Integrated control

05500 Social biology and human ecology

12510 Pathology - Necrosis

54600 Pest control: general, pesticides and herbicides

60008 Economic entomology - Stored products

64076 Invertebrata: comparative, experimental morphology, physiology and pathology - Insecta: physiology

#### **Biosystematic Codes:**

75330 Lepidoptera

26775 Solanaceae

**Abstract:** ...affecting tubers in Tunisian rustic stores. Exponential curve of death. i.e., constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors. which permits to judge different control strategies. In...

10/5,K/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14377618 **Biosis No.:** 199800171865

#### **Cost-identification analysis in oral cavity cancer management**

**Author:** Funk Gerry F (Reprint); Hoffman Henry T; Karnell Lucy Hynds; Ricks Joan M; Zimmerman M Bridget; Corbae Dean P; Hussey David H; McCulloch Timothy M; Graham Scott M; Dawson Cindy J; Means Mary E; Colwill Margaret L; Titler Marita G; Smith Elaine M

**Author Address:** Dep. Otolaryngol.-Head Neck Surg., 200 Hawkins Dr., Room E230GH, Univ. Iowa Hosp. Clin., Iowa City, IA 52242, USA\*\*USA

**Journal:** Otolaryngology - Head and Neck Surgery 118 ( 2 ): p 211-220 Feb., 1998 1998

**Medium:** print

**ISSN:** 0194-5998

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** The objectives of this study were to investigate potential relationships between pretreatment patient-mix characteristics, treatment modalities, and costs generated during the pretreatment work-up, treatment, and 1-year follow-up periods for patients with oral cavity cancer (OCC). Another objective was to identify potential areas for cost reduction and improved **resource allocation** in the **management** of OCC patients. Using a **retrospective cohort** of 73 patients with OCC, pretreatment patient-mix characteristics and treatment modalities were evaluated in relation to university-based charges incurred during the pretreatment evaluation, treatment, and 1-year follow-up periods. Simple regression and stepwise multiple regression analyses were used to develop predictive models for cost based on independent variables, including age, AJCC TNM clinical stage, smoking history, American Society of Anesthesiologists (ASA) class, comorbidity as defined by the Kaplan-Feinstein grade and treatment modality. The dependent measurements included all physician, office, and hospital charges incurred at the University of Iowa Hospitals and Clinics during the pretreatment evaluation, treatment, and follow-up periods, as well as the total pretreatment through 1-year follow-up management costs. Independent variables that were identified as being significantly associated with treatment costs included T classification, N classification, TNM stage, unimodality versus multimodality treatment, and the Kaplan-Feinstein comorbidity grade. Age, smoking status, and ASA class were not significantly associated with costs. The majority of the OCC management costs were incurred during the treatment period. The most substantial decreases in management costs for OCC will be realized through measures that allow identification and treatment of disease at an early stage, in which single-modality treatment may effectively be used. Resource allocation for OCC should support the investigation of measures through which the diagnosis and treatment of OCC at the earliest possible stage is facilitated. The presence of comorbid illness is a significant component in the determination of management costs for OCC and should be included in analyses of resource allocation for OCC. The singular diagnosis of OCC encompasses a wide range of patient illness severity, and diagnosis-related reimbursement schemes for OCC treatment should optimally differentiate between early and advanced stage disease.

#### **DESCRIPTORS:**

**Major Concepts:** Dental Medicine--Human Medicine, Medical Sciences; Oncology--Human Medicine, Medical Sciences; Public Health--Allied Medical Sciences

**Biosystematic Names:** Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

**Organisms:** human (Hominidae)--patient

**Common Taxonomic Terms:** Animals; Chordates; Humans; Mammals; Primates; Vertebrates

**Diseases:** oral cavity cancer

**Mesh Terms:** Mouth Neoplasms (MeSH)

**Miscellaneous Terms:** **Concept Codes:** cost reduction; diagnosis-related reimbursement scheme; illness severity; pretreatment patient-mix characteristics; resource allocation

**Concept Codes:**

37010 Public health - Public health administration and statistics  
12504 Pathology - Diagnostic  
19006 Dental - Pathology  
24004 Neoplasms - Pathology, clinical aspects and systemic effects  
37012 Public health - Health services and medical care

**Biosystematic Codes:**

86215 Hominidae

**Abstract:** ...and 1-year follow-up periods for patients with oral cavity cancer (OCC). Another objective was to identify potential areas for cost reduction and improved **resource allocation** in the **management** of OCC patients. Using a **retrospective cohort** of 73 patients with OCC, pretreatment patient-mix characteristics and treatment modalities were evaluated in relation to university-based charges incurred during the pretreatment evaluation...

## II. Inventor Search

### A. Dialog

File 347:JAPIO Dec 1976-2009/Jan(Updated 090503)

(c) 2009 JPO & JAPIO

File 348:EUROPEAN PATENTS 1978-200926

(c) 2009 European Patent Office

File 349:PCT FULLTEXT 1979-2009/UB=20090618|UT=20090611

(c) 2009 WIPO/Thomson

File 350:Derwent WPIX 1963-2009/UD=200939

(c) 2009 Thomson Reuters

Set	Items	Description
S1	978	AU=(WILSON, T? OR WILSON T?)
S2	4	S1 AND COHORT?
S3	4	IDPAT (sorted in duplicate/non-duplicate order)

2/3K/1 (Item 1 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2009 WIPO/Thomson. All rights reserved.

00975224

**METHOD AND SYSTEM FOR ANALYZING RESOURCE ALLOCATION**  
**PROCEDE ET SYSTEME D'ANALYSE D'AFFECTATION DE RESSOURCES**

#### **Patent Applicant/Inventor:**

- WILSON Thomas W  
809 Almahurst Lane, Loveland, OH 45140; US; US(Residence); US(Nationality);
  - WILSON Thomas W...
- ;; ;

#### **Legal Representative:**

- SMITH Mark F(agent)  
7577 Central Park Boulevard, Suite 316, Mason, OH 45040; US;



	Country	Number	Kind	Date
Patent	WO	200305162	A2-A3	20030116
Application	WO	2002US21225		20020702
Priorities	US	2001302430		20010702
	US	2002358284		20020220
	US	2002362146		20020306

**Designated States:** (All protection types applied unless otherwise stated - for applications 2004+)

[EP] AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;  
FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;  
SE; SK; TR;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZM; ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Language Publication Language: English

Filing Language: English

Fulltext word count: 11948

#### English Abstract:

...per a unique unit of analysis (e.g. UOA-ID) that meets the criteria for inclusion into a specific Population (Type) into information organized by **Cohort** Time and summarized across all UOA-Ids that are part of the same Population. An Eligible Adjusted Variable Value (EAV) can be calculated for each time segment and summarized across all the UOA-IDs to enable one to estimate resources that can be allocated per UOA-ID per **Cohort** time segment to reach a defined outcome based on a defined return on resource allocation estimate.

#### French Abstract:

...analyse (telle que UOA-ID) conforme aux criteres d'appartenance dans une population specifique (Type) et on aboutit a des informations organisees par temps de **cohorte** et qui sont recapitulees pour l'ensemble des UOA-appartenant a cette meme population. Une valeur de variable EAV peut etre calculee pour chaque segment... ..recapitulee pour l'ensemble des UOA-ID pour permettre de calculer les ressources susceptibles d'etre affectees par UOA-ID par segment de temps de **cohorte** pour obtenir une issue definie sur la base d'un retour defini sur affectation de ressource estimee.

#### Detailed Description:

...business organization will be better able to analyze and evaluate the resources that will be necessary to achieve a specific outcome by first understanding this "Cohort Time" heterogeneity of any population during any calendar (or clock) time period.

By way of illustration, manufactures, such as automobile manufactures, are actively searching for...generating an Output Expression.

In another preferred embodiment of the invention the method further comprises the step of transforming the Output Expression from expressed in Cohort time segments to being expressed in CCT segments.

I 0 In another embodiment of the invention the method for analyzing resource allocation is performed using...Grouper can be equivalent to type, in that case it is a many-to-few algorithm); identi@ @ing a Start Time; forming at least one Cohort time segment based on the Start Time; adjusting and standardizing the I ...invention is an Output Expression for use in analyzing resource allocation comprising a representation showing trends of a particular Population, said trends are expressed in Cohort time segments.

In another preferred embodiment of the invention, an Output Expression is generated by the method comprising the stop of calculating an Eligible Adjusted...more desirable in certain studies to use a calendar month, regardless of its duration, as a definition of a time segment. In that case, some cohort months

#### TABLE 4

STEP 6: FORM TIME SEGMENTS FOR EACH UOA4D (PROSPECTIVE + AND RETROSPECTIVE), BASED ON START TIME.

UOA-ID Type Start Time Grouper TS...information databank forthe appropriate time segment, as represented by Table 5. In this way, VAR Values are changed from being tracked by calendar time to Cohort Time. As used herein "Cohort Time" means that the Start Time is based on a defining event, which is the last date/clock time that the individual UOA-ID meets all of the eligibility criteria to be included into the population. Thus, in Cohort Time, the start of TS+I (Index month) will be the date or time all of the eligibility criteria is met per UOMD, not the In a monthbased Cohort Time, the first individual first month would be January 1 - 31, 2001, and the second individual's first month would be December 1 - 31, 2001. Thus, in Cohort Time, however, both individuals would be counted in month 1, however, in months 2 to 12, the first individual would be counted while the second...also the first day of the study, a study which operationally ended December 31, 2001'. Accordingly, the individual's prospective Potential Eligibility Score is 12 Cohort months out of a possible 12 Cohort months (equivalent in this case to the 12 calendar months of the study). However, the individual's retrospective Potential Eligibility Score is based upon zero (0) retrospective Cohort months out of a possible 12 retrospective Cohort months (this score is 12 because any UOA-ID, could have "started" on December 31, 2001 and would therefore would be a maximum or potential...divided by 12, which will default to zero by the algorithm). The I 0 second individual who "started" on December 1, 2001 has one prospective Cohort month out of a possible 12 Cohort months of prospective eligibility so the individual's prospective Potential Eligibility Score is a function of 1 out of 12 (e.g. 1 divided by...time (CCT). Coupled with eligibility to experience a transaction, the method and system for utilizing the method of the present invention transforms these data into Cohort time trends of utilization (e.g. cost) per Type. These trends are then used to 1) better understand current trends in Cohort Time, and 2) to

better estimate resource allocation to meet specific, goals of improving utilization over **Cohort** Time or CCT.

For this example, the UOAs are specific patients within a defined Population and the UOA-ID is a unique individual who meets...and the system of the present invention uses an individual view of an individual advertisement (Type) and transforms this into a trend of viewship over **Cohort** Time per Type (or Grouper) in the population. These trends can be used to understand the current time segment "view" per advertisement (comparisons to ...this case the VAR Value is multiplied by eligibility value to generate an EAV.

Generate an Output Expression(s)

Display trends in "percent selected" over **Cohort** time segments without regard to stratifying variable (Product).

Calculated trend of population "selecting" product A (trademark 12 owners product) vs. Product B (infringing product) per... here  
 \*\*NNT is based on the rounded value as an integer.

It should now be apparent that with all of the various Output Expressions, the **Cohort** Time trend calculated per group (or sub-group) can be compared to other groups (or subgroups). This can be based on Type or another variable...stratify by this variable, calculating trends, and RA, O, and RORA.

It should be now be apparent to those skilled in the art that these **Cohort** Time calculations can be easily translated back into CCT for financial budgeting and reporting. This can be accomplished by inclusion of the "Start Time" CCT into data set per UOA-ID by Type/Grouper. That is, using the resources allocation estimates per **cohort** time segment, these time segment specific estimates can be place back into CCT to estimate resources allocated per CCT time segment. This is accomplished by maintaining the start CCT per UOA-ID in the set of information. See Table 25 for example the simple method of transforming **Cohort** Time values for budgeting per calendar time.

TABLE 26

Distribution per DV=I DV=O Total RA

Calendar Time (expected (expected (expected ESTIMATE

Segment (equal in percentage) percentage) percentage) S (per UOA duration to **Cohort** ID)\*

TS)

TS+1 (index TS) 37.6% 62.4% 100.0 \$255

TS+2 8.4 91.6 100.0 \$47

TS+3 8...0 \$36

TS+6 3.1 96.9 100.0 \$23

Column Sum/ 69.99% / 6 529.99% / 6 600 / 6 \$456 / 6

Number of **Cohort**

Time Segment

Budget Estimates 11.67 % 88.33 % 100.0 % \$76

(ColumnAverage)

Key to table: \*Resource Allocation (RA) Estimates (where Outcome expectation 1 0% and Return on

Resource Allocation = 1.0) The calculations are based on a equal weighting of 1 5 UOA-ID per **Cohort** time segment. Thus (1 00 / 6 or 16.66%) of the total Population during any calendar time segment is in any of the six **Cohort** Time segments. A simple weighting system can be applied to alter the column average.

Further, it should also now be apparent to those skilled in the art that the criteria for inclusion into a specific Population (Type or Group) into information organized by **Cohort** Time and summarized across all UOA-IDs that are part of the same Population. This is accomplished by determining the time segment and its duration...EAV. The EAVs can be summarized across all the UOA-IDs to enable one to estimate resources that can be allocated per UOA-ID per **Cohort** time segment to reach a defined outcome based on a defined return on resource allocation estimate.

It has been found and should be understood to...

#### Claims:

...UOA-ID, a CCT, and a VAR Value;

grouping each UOA-ID into an appropriate Type; identifying a Start Time; forming at least one **Cohort** time segment based on the Start Time; placing the UOA-ID into the appropriate time segment; and calculating an eligibility score for each UOA step of transforming the Output 1 5 Expression from expressed in **Cohort** time segments to being expressed in CCT segments.

3 The method of Claim 1 wherein said method is performed using a system comprising a central...UOA-ID); and generating an Output Expression.

17 The method of Claim 16 further comprising the step of transforming the Output Expression from expressed in **Cohort** time segments to being expressed in CCT segments.

18 The method of Claim 16 wherein said method is performed using a system comprising a central... an UOA-ID, a CCT, and a VAR Value;

grouping each UOA-ID into an appropriate Type; identifying a Start Time; forming at least one **Cohort** Time segment based on the Start Time; placing the VAR Value into the appropriate time segment; and calculating an eligibility score for each UOA...infringement applications, and health care applications.

36 An Output Expression comprising a representation showing EAV trends of a particular Population, said trends are expressed in **Cohort** time segments.

37 An Output Expression comprising a representation showing NNT trends of a particular Population, said trends are expressed in **Cohort** time segments.

38 An Output Expression comprising a representation showing EAV Net Value trends of a particular Population, said trends are expressed in **Cohort** time segments.

**Dialog eLink:** [Order File History](#)

2/3,K/4 (Item 3 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0013042041 *Drawing available*

WPI Acc no: 2003-121329/200311

XRPX Acc No: N2003-096588

**Analyzing method for resource allocation to achieve specified outcomes transforming economic and eligibility information produced over calendar/clock time per a unique unit of analysis**

Patent Assignee: WILSON T W (WILS-I)

Inventor: **WILSON T W**

Patent Family ( 4 patents, 99 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2003005162	A2	20030116	WO 2002US21225	A	20020702	200311	B
EP 1425681	A2	20040609	EP 2002749796	A	20020702	200438	E
			WO 2002US21225	A	20020702		
AU 2002320286	A1	20030121	AU 2002320286	A	20020702	200452	E
AU 2002320286	A8	20051013	AU 2002320286	A	20020702	200616	E

Priority Applications (no., kind, date): US 2001302430 P 20010702; US 2002358284 P 20020220; US 2002362146 P 20020306

Patent Details						
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
WO 2003005162	A2	EN	57	6		
National Designated States,Original	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
Regional Designated States,Original	AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
EP 1425681	A2	EN			PCT Application	WO 2002US21225
					Based on OPI patent	WO 2003005162
Regional	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC					

Designated States,Original	MK NL PT RO SE SI SK TR					
AU 2002320286	A1	EN			Based on OPI patent	WO 2003005162
AU 2002320286	A8	EN			Based on OPI patent	WO 2003005162

Inventor: **WILSON T W** Alerting Abstract ... UOA-ID, a CT and a VAR value. Each UOA-ID is grouped into an appropriate Type. A Start Time is identified. At least one **Cohort** time segment is formed based on the Start Time. The UOA-ID is placed into the appropriate time segment. An eligibility score is calculated for... Original Publication Data by AuthorityArgentina**Publication No.** Inventor name & address:**WILSON T W... ..WILSON T W... ..Wilson, Thomas W... ..WILSON, Thomas, W ...Original Abstracts:**per a unique unit of analysis (e.g. UOA-ID) that meets the criteria for inclusion into a specific Population (Type) into information organized by **Cohort** Time and summarized **across** all UOA-Ids that are part of the same Population. An Eligible Adjusted Variable Value (EAV) can be calculated for each time segment and summarized across all the UOA-IDs to enable one to estimate resources that can be allocated per UOA-ID per **Cohort** time segment to **reach** a defined outcome based on a defined return on resource allocation estimate... .. per a unique unit of analysis (e.g. UOA-ID) that meets the criteria for inclusion into a specific Population (Type) into information organized by **Cohort** Time and summarized across all UOA-Ids that are part of the same Population. An Eligible Adjusted Variable Value (EAV) can be calculated for each time segment and summarized across all the UOA-IDs to enable one to estimate resources that can be allocated per UOA-ID per **Cohort** time segment to reach a defined outcome based on a defined return on resource allocation estimate... ..

File 149:TGG Health&Wellness DB(SM) 1976-2009/May W4

(c) 2009 Gale/Cengage

File 444:New England Journal of Med. 1985-2009/Jun W3

(c) 2009 Mass. Med. Soc.

File 15:ABI/Inform(R) 1971-2009/Jun 24

(c) 2009 ProQuest Info&Learning

File 9:Business & Industry(R) Jul/1994-2009/Jun 24

(c) 2009 Gale/Cengage

File 610:Business Wire 1999-2009/Jun 25

(c) 2009 Business Wire.

File 810:Business Wire 1986-1999/Feb 28

(c) 1999 Business Wire

File 275:Gale Group Computer DB(TM) 1983-2009/May 28

(c) 2009 Gale/Cengage

File 624:McGraw-Hill Publications 1985-2009/Jun 25

(c) 2009 McGraw-Hill Co. Inc

File 621:Gale Group New Prod.Annou.(R) 1985-2009/May 20

(c) 2009 Gale/Cengage

File 636:Gale Group Newsletter DB(TM) 1987-2009/Jun 03

(c) 2009 Gale/Cengage  
 File 613:PR Newswire 1999-2009/Jun 24  
 (c) 2009 PR Newswire Association Inc  
 File 813:PR Newswire 1987-1999/Apr 30  
 (c) 1999 PR Newswire Association Inc  
 File 16:Gale Group PROMT(R) 1990-2009/Jun 03  
 (c) 2009 Gale/Cengage  
 File 160:Gale Group PROMT(R) 1972-1989  
 (c) 1999 The Gale Group  
 File 634:San Jose Mercury Jun 1985-2009/Jun 24  
 (c) 2009 San Jose Mercury News  
 File 148:Gale Group Trade & Industry DB 1976-2009/Jun 10  
 (c) 2009 Gale/Cengage  
 File 20:Dialog Global Reporter 1997-2009/Jun 25  
 (c) 2009 Dialog  
 File 65:Inside Conferences 1993-2009/Jun 25  
 (c) 2009 BLDSC all rts. reserv.  
 File 2:INSPEC 1898-2009/Jun W2  
 (c) 2009 The IET  
 File 474:New York Times Abs 1969-2009/Jun 25  
 (c) 2009 The New York Times  
 File 475:Wall Street Journal Abs 1973-2009/Jun 25  
 (c) 2009 The New York Times  
 File 99:Wilson Appl. Sci & Tech Abs 1983-2009/May  
 (c) 2009 The HW Wilson Co.  
 File 256:TecInfoSource 82-2009/May  
 (c)2009Info.Sources Inc.All rights reserved  
 File 8:Ei Compendex(R) 1884-2009/Jun W2  
 (c) 2009 Elsevier Eng. Info. Inc.  
 File 6:NTIS 1964-2009/Jun W4  
 (c) 2009 NTIS, Intl Cpyrght All Rights Res  
 File 34:SciSearch(R) Cited Ref Sci 1990-2009/Jun W2  
 (c) 2009 The Thomson Corp  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
 (c) 2006 The Thomson Corp  
 File 7:Social SciSearch(R) 1972-2009/Jun W3  
 (c) 2009 The Thomson Corp  
 File 5:Biosis Previews(R) 1926-2009/Jun W3  
 (c) 2009 The Thomson Corporation  
 File 73:EMBASE 1974-2009/Jun 23  
 (c) 2009 Elsevier B.V.  
 File 155:MEDLINE(R) 1950-2009/Jun 24  
 (c) format only 2009 Dialog

Set	Items	Description
S1	17489	AU=(WILSON, T? OR WILSON T?)

S2	189	S1 AND COHORT
S3	0	S2 AND (RESOURCE? (2N) ALLOCAT?)
S4	29	S1 AND COHORTS
S5	11	RD (unique items)
S6	0	S5 AND RESOURCE?
S7	1	S5 AND ALLOCAT?

5/3,K/6 (Item 3 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

16656086 Genuine Article#: 184DA No. References: 16

**Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents**

**Author:** Blackburn DF (REPRINT) ; Lamb DA; Eurich DT; Johnson JA; **Wilson TW**; Dobson RT; Blackburn JL

**Corporate Source:** Univ Saskatchewan, Coll Pharm & Nutr, 110 Sci Pl/Saskatoon/SK S7N 5C9/Canada/ (REPRINT); Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon/SK S7N 5C9/Canada/; Univ

Saskatchewan, Coll Pharm & Nutr, Saskatoon/SK/Canada/; Univ Saskatchewan, Coll Med, Saskatoon/SK/Canada/; Univ Alberta, Inst Hlth Econ, Dept Publ Hlth Sci, Edmonton/AB/Canada/

**Journal:** JOURNAL OF HYPERTENSION , 2007 , V 25 , N7 ( JUL ) , P 1499-1505

**ISSN:** 0263-6352 **Publication date:** 20070700

**Publisher:** LIPPINCOTT WILLIAMS & WILKINS , 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA

**Language:** English **Document Type:** ARTICLE ( ABSTRACT AVAILABLE )

**Author:** Blackburn DF (REPRINT) ; Lamb DA; Eurich DT; Johnson JA; **Wilson TW**; Dobson RT; Blackburn JL

**Abstract:** ...of Saskatchewan, Canada. Eligible subjects were first-ever users of antihypertensive medications between 1 January 1994 and 31 December 2003 and were grouped into four **cohorts**: atenolol, angiotensin-converting enzyme inhibitors (ACEI), thiazide diuretics, or calcium antagonists. Patients remained eligible during monotherapy only.

**Results** We identified 19 249 eligible individuals ( mean... ..a mean of 2.3 years (SD 2.0). The rate of myocardial infarction, unstable angina, stroke, or death occurred in similar frequencies among all **cohorts**: atenolol (2.3%), ACEI (3.6%), thiazide diuretics (2.9%), and calcium antagonists (3.9%). After adjustment for potential confounders, atenolol therapy was not associated... ..hazard ratios ranging between 1.03 [95% confidence intervals (CI) 0.72-1.46] and 1.24 (95% CI 0.91-1.68) for all **cohorts** compared with atenolol. Similar results were observed upon stratifying the sample into subjects above and below 60 years of age.

**Conclusion** The low event rates for all **cohorts** suggest that atenolol has not been associated with a significant burden of cardiovascular morbidity or mortality in its traditional role for uncomplicated hypertension. Further study...

**Identifiers--**



---

5/3,K/1 (Item 1 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01477153    **Supplier Number:** 15139791 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Childhood and adult socioeconomic status as predictors of mortality in Finland.**

Lynch, John W.; Kaplan, George A.; Cohen, Richard D.; Kauhanen, Jussi; **Wilson, Thomas W.**; Smith, Nicholas L.; Salonen, Jukka T.  
The Lancet , v343 , n8896 , p524(4)  
Feb 26 ,  
1994

**Publication Format:** Magazine/Journal  
**ISSN:** 0099-5355  
**Language:** English  
**Record Type:** Fulltext; Abstract **Target Audience:** Professional  
**Word Count:** 3047    **Line Count:** 00255

...**Wilson, Thomas W**

...socioeconomic conditions in childhood are important factors in adult health. We caution against this interpretation. Firstly, these results largely reflect the mortality experience of study **cohorts** aged 54 and 60 years; with the relatively short follow-up, only 13 of the 166 deaths occurred in the **cohorts** aged 42 or 48. Furthermore, as the 54-year-old cohort accounted for almost 60% of the sample, it is worth noting that this group...

### III. Text Search Results from Dialog (Full Text dbs)

#### A. Full-Text Databases – PATENT

#### **File 348:EUROPEAN PATENTS 1978-200926**

##### **(c) 2009 European Patent Office**

#### **File 349:PCT FULLTEXT 1979-2009/UB=20090625|UT=20090618**

##### **(c) 2009 WIPO/Thomson**

Set	Items	Description
S1	113518	(ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR DIVID?())UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?)(3N)(RESOURC? OR CAPITAL OR AVAILABLE()MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR)
S2	14529	(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N)(INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR REPAR? OR CORRECTION? OR CORRECTIV?)
S3	7	COHORT()TIME OR RETROSPECT?()COHORT?
S4	0	S3 NOT AY>2003
S5	5518	(UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA()POINT? OR ENTITY OR ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N)(POPULATION OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO()OBSERV? OR TESTING OR TRIAL? OR STUDY OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)
S6	2485	(PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR START?()("FROM" OR WITH)) (4N)(DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR (CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N)(DEFIN? OR DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR ARRIV?()AT OR ASSIGN?))
S7	3222	(PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT? OR RANGE?) OR TIMES OR DURATION OR DURING(2N)TERM OR LONG() (TERM OR RANGE) ) (4N)(AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W)(MARKET? OR CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)
S8	5323	(DURATION OR TIME? OR PERIOD? OR (AFTER OR "FROM") (2W)(START? OR COMMENC?) OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV? OR WINDOW?) (4N)(TREATMENT? OR INTERVENTION? OR THERAP? OR REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINISTRATION?)
S9	502	S8 AND S7 AND S6 AND S5
S10	101	S9(12N)S1
S11	60	S10 NOT AY>2003
S12	60	IDPAT (sorted in duplicate/non-duplicate order)
S13	60	IDPAT (primary/non-duplicate records only)
S14	10	S13(24N)S2

14/3K/7 (Item 6 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2009 WIPO/Thomson. All rights reserved.

00756315

**DATA PROCESSING SYSTEM FOR PATIENT OUTCOME AND RISK BENCHMARKING  
AND HEALTHCARE DATA BASE MANAGEMENT**  
SYSTEME DE TRAITEMENT DE DONNEES POUR L'ESTIMATION DES RISQUES ENCOURUS  
PAR UN PATIENT ET DES RESULTATS PROBABLES CHEZ CE PATIENT ET POUR LA  
GESTION D'UNE BASE DE DONNEES DE SANTE

**Patent Applicant/Patent Assignee:**

- **PHARMACON GLOBAL ENTERPRISES LLC**; The Empire State Building, 350 Fifth Avenue, Ste. 5110, New York, NY 10118  
US; US(Residence); US(Nationality)  
(For all designated states except: US)
- **ARNOLD Renee J Goldberg**; 60 West 68th Street, Apt. 4D, New York, NY 10023  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **PETTIT Krista**; 61 East 86th Street, Apt. 31, New York, NY 10028  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **HARJONO Harry**; 128 Glenwood Court, Union, NJ 07083  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **ZHOU Yonglong**; 104-61, 41 Avenue, Flushing, NY 11368  
US; US(Residence); US(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

- **ARNOLD Renee J Goldberg**  
60 West 68th Street, Apt. 4D, New York, NY 10023; US; US(Residence); US(Nationality);  
(Designated only for: US)
- **PETTIT Krista**  
61 East 86th Street, Apt. 31, New York, NY 10028; US; US(Residence); US(Nationality);  
(Designated only for: US)
- **HARJONO Harry**  
128 Glenwood Court, Union, NJ 07083; US; US(Residence); US(Nationality); (Designated only  
for: US)

- **ZHOU Yonglong**  
104-61, 41 Avenue, Flushing, NY 11368; US; US(Residence); US(Nationality); (Designated only for: US)

**Legal Representative:**

- **KANIECKI Diana J**  
321 Avenue C, Apt. 10E, New York, NY 10009; US;

	Country	Number	Kind	Date
Patent	WO	200069331	A1	20001123
Application	WO	2000US13267		20000515
Priorities	US	99134412		19990517

**Designated States:** (All protection types applied unless otherwise stated - for applications 2004+)

[EP] AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG;  
ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

**Language** Publication Language: English

Filing Language: English

Fulltext word count: 32620

**Detailed Description:**

...management of otitis media.

**Rationale**

Otitis media represents a costly disease state that is frequently encountered by clinicians. In order to select the most cost-**effective treatment** option, clinicians need to consider various factors such as local resistance patterns, adverse effects of the antibiotics, and **resource** use associated with **managing** successfully-treated patients as well as treatment failures. Such information may not be readily available to the clinician at the point of prescribing. The AOM...

14/3K/9 (Item 8 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2009 WIPO/Thomson. All rights reserved.

00737652

**GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE**

VARIATIONS DE SEQUENCES GENIQUES PRESENTANT UNE UTILITE POUR LA  
SELECTION DU TRAITEMENT D'UNE MALADIE

**Patent Applicant/Patent Assignee:**

- **VARIAGENICS INC**; 60 Hampshire Street, Cambridge, MA 02139-1562  
US; US(Residence); US(Nationality)  
(For all designated states except: US)
- **STANTON Vincent Jr**; 32 Royal Road, Belmont, MA 02173  
US; US(Residence); US(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

- **STANTON Vincent Jr**  
32 Royal Road, Belmont, MA 02173; US; US(Residence); US(Nationality); (Designated only for: US)

**Legal Representative:**

- **AMES Wesley B(agent)**  
Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130; US;

	Country	Number	Kind	Date
Patent	WO	200050639	A2-A3	20000831
Application	WO	2000US1392		20000120
Priorities	US	99121047		19990222
	US	99139440		19990615
	US	99357743		19990720

**Designated States:** (All protection types applied unless otherwise stated - for applications 2004+)

[EP] AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG;  
ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

**Language** Publication Language: English

Filing Language: English

Fulltext word count: 315309

### Detailed Description:

...diagnostic test, may be the only means of getting regulatory approval for a drug. As  
Innovative  
healthcare becomes increasingly costly, the ability to **allocate** healthcare **resources effectively** becomes  
increasingly urgent. The use of genetic tests to develop and rationally administer medicines represents a  
powerful tool for accomplishing more cost **effective** medical care.

#### Inflammation and Immune Disease

In this application, we further address the difficulties that arise in treating inflammatory diseases and  
other diseases in which...Parkinson's disease, dementia, demyelinating disease, amyotrophic lateral  
sclerosis, and Huntington's disease.

Specifically, this invention describes the identification of genes and gene sequence variances **useful** in  
the field of **therapeutics** for optimizing efficacy and safety of drug therapy by allowing prediction of  
pharmacokinetic and/or toxicologic behavior of specific drugs in specific **patients**. Relevant  
pharmacokinetic processes include absorption, distribution, metabolism and excretion. Relevant  
toxicological processes include both dose related and idiosyncratic adverse reactions to drugs, including,  
for example...or is a cDNA derived from an mRNA of the gene.

In another aspect, the invention provides a method for determining a  
genotype of an **individual** in relation to one or more variances in one or more of the .genes identified in  
above aspects by using mass spectrometric determination of a...one skilled in the art to identify  
therapeutically relevant genes in patients with one of the listed indications for the purposes of  
stratification of these **patients** based upon genotype and subsequent correlation of genotype with drug  
response. The shaded intersections indicate preferred sets of genes for  
- understanding the basis of interpatient

## B. Full-Text Databases – NON-PATENT

**File 15:ABI/Inform(R) 1971-2009/Jun 29**  
(c) 2009 ProQuest Info&Learning

**File 9:Business & Industry(R) Jul/1994-2009/Jun 27**  
(c) 2009 Gale/Cengage

**File 610:Business Wire 1999-2009/Jun 30**  
(c) 2009 Business Wire.

**File 810:Business Wire 1986-1999/Feb 28**  
(c) 1999 Business Wire

**File 275:Gale Group Computer DB(TM) 1983-2009/Jun 02**  
(c) 2009 Gale/Cengage

**File 624:McGraw-Hill Publications 1985-2009/Jun 30**  
(c) 2009 McGraw-Hill Co. Inc

**File 621:Gale Group New Prod.Annou.(R) 1985-2009/May 25**  
(c) 2009 Gale/Cengage

**File 636:Gale Group Newsletter DB(TM) 1987-2009/Jun 08**  
(c) 2009 Gale/Cengage

**File 613:PR Newswire 1999-2009/Jun 30**  
(c) 2009 PR Newswire Association Inc

**File 813:PR Newswire 1987-1999/Apr 30**  
(c) 1999 PR Newswire Association Inc

**File 16:Gale Group PROMT(R) 1990-2009/Jun 08**  
(c) 2009 Gale/Cengage

**File 160:Gale Group PROMT(R) 1972-1989**  
(c) 1999 The Gale Group

**File 634:San Jose Mercury Jun 1985-2009/Jun 28**  
(c) 2009 San Jose Mercury News

**File 148:Gale Group Trade & Industry DB 1976-2009/Jun 15**  
(c) 2009 Gale/Cengage

**File 20:Dialog Global Reporter 1997-2009/Jun 30**  
(c) 2009 Dialog

Set	Items	Description
S1	1093	COHORT()TIME OR RETROSPECT?()COHORT?
S2	55	S1 AND ((ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR DIVID?()UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?)(3N)(RESOURC? OR CAPITAL OR AVAILABLE()MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR))
S3	27	S2 NOT PY>2003
S4	27	RD (unique items)
S5	246	(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N)(INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR CORRECTION? OR CORRECTIV?)

S6            23    (ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR  
DIVID?())UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?) (3N) (RESOURC? OR CAPITAL OR  
AVAILABLE())MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR  
DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR)

S7            23    (UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA()POINT? OR ENTITY OR  
ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N) (POPULATION  
OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO()OBSERV? OR TESTING OR TRIAL? OR STUDY  
OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)

S8            5    (PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR  
FOLLOWING OR SUBSEQUENT()TO OR SINCE OR START?()) ("FROM"  
OR WITH)) (4N) (DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR  
(CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N) (DEFIN? OR  
DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR  
ARRIV?())AT OR ASSIGN?))

S9            10    (PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT?  
OR RANGE?) OR TIMES OR DURATION OR DURING(2N)TERM OR LONG() (TERM OR RANGE)  
) (4N) (AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W) (MARKET? OR  
CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)

S10           19    (DURATION OR TIME? OR PERIOD? OR (AFTER OR  
"FROM") (2W) (START? OR COMMENC?) OR FOLLOWING OR  
SUBSEQUENT()TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV?  
OR WINDOW?) (4N) (TREATMENT? OR INTERVENTION? OR THERAP? OR  
REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINISTRATION?)

S11           23    S10 OR S9 OR S8 OR S7 OR S6

S12           16    S11(50N)S5

S13           16    RD   (unique items)

S14           9    S13 NOT PY>2003

14/3,K/4 (Item 1 from file: 148)  
DIALOG(R)File 148: Gale Group Trade & Industry DB  
(c) 2009 Gale/Cengage. All rights reserved.

15979263    **Supplier Number:** 103731431 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Length of stay, conditional length of stay, and prolonged stay in pediatric asthma. (Access in  
Chronic Care).(a study finds the overall management of asthma admissions appears more efficient  
in Pennsylvania than in New York)(Illustration)**

Silber, Jeffrey H.; Rosenbaum, Paul R.; Even-Shoshan, Orit; Shabbout, Mayadah; Zhang, Xuemei;  
Bradlow, Eric T.; Marsh, Roger R.  
Health Services Research , 38 , 3 , 867(20)  
June , 2003

**Document Type:** Illustration

ISSN: 0017-9124

**Language:** English

**Record Type:** Fulltext; Abstract

**Word Count:** 7080    **Line Count:** 00725

...stay" (CLOS)) (Silber et al. 1999b), this report aims to provide insight  
into state, city, and hospital differences in the patterns of stay for  
asthma **patients**. Through this approach, we aim to aid policymakers  
to better understand some potential etiologies for these differences, so



that future policy initiatives can better focus on likely avenues for **successful interventions**.

METHODS

**Patient Population**

We obtained claims data on all pediatric admissions ages 1-17 in Pennsylvania for the period 1/1/96-12/31/98 and in New York State for the period 1/1/96-9/30/98. **Patients** admitted to psychiatric and nonacute care hospitals were not included in this study. Data from Pennsylvania were provided through the Pennsylvania Health Care Cost Containment...

---

14/3,K/5 (Item 2 from file: 148)

DIALOG(R)File 148: Gale Group Trade & Industry DB

(c) 2009 Gale/Cengage. All rights reserved.

13630586 **Supplier Number: 76612720 (USE FORMAT 7 OR 9 FOR FULL TEXT )**

**Asthma Prevalence, Cost, and Adherence with Expert Guidelines on the Utilization of Health Care Services and Costs in a State Medicaid Population.(Statistical Data Included)**

Piecoro, Lance T.; Potoski, Matthew; Talbert, Jeff C.; Doherty, Dennis E.

Health Services Research , 36 , 2 , 357

June , 2001

**Document Type:** Statistical Data Included

ISSN: 0017-9124

**Language:** English

**Record Type:** Fulltext

**Word Count:** 5427 **Line Count:** 00546

...was associated with increased asthmarelated ER care and hospitalizations. Studying the costs and appropriateness of asthma therapy will provide insight into how current health care **resources** are **allocated** and how treatment alternatives affect costs and **patient** health. The **analysis** presented in this article can help guide future health policy and resources to create more cost-**effective therapies** for asthma in Medicaid populations.

METHODS

Data for this study were extracted from a database containing over 20 million paid claims for pharmacy, institutional (hospital...

4/3,K/3 (Item 3 from file: 15)

DIALOG(R)File 15: ABI/Inform(R)

(c) 2009 ProQuest Info&Learning. All rights reserved.

02198253 75498825

**Raw oyster consumption and outbreaks of viral gastroenteritis in New Zealand: Evidence for risk to the public's health**

Simmons, Greg; Greening, Gail; Gao, Wanzhen; Campbell, Donald  
Australian & New Zealand Journal of Public Health v25n3 pp: 234-240  
Jun 2001  
**ISSN:** 1326-0200 **Journal Code:** AUP  
**Word Count:** 4551

**Abstract:**

...Pacific half shell oysters and outbreaks of Norwalk-like virus (NLV) gastroenteritis in Auckland in the last third of 1999. Ten outbreaks were investigated as **retrospective cohorts** using standardized questionnaires relating to food and drink exposures. Trace back of oysters and site inspections of implicated commercial growing areas were performed. The epidemiological...

**Text:**

...half shell oysters and outbreaks of Norwalk-like virus (NLV) gastroenteritis in Auckland in the last third of 1999.

Method: Ten outbreaks were investigated as **retrospective cohorts** using standardised questionnaires relating to food and drink exposures. Trace back of oysters and site inspections of implicated commercial growing areas were performed. Virological analyses...of oyster growing areas. This, coupled with proven faecal contamination of oysters was established for the Awaawaroa Bay growing site. New provisions contained in the **Resource Management** (Marine Pollution) Regulations 1998 aim to reduce the impact of human sewage contamination of marine waters. However, the regulations permit the discharge of treated sewage...

---

4/3,K/4 (Item 4 from file: 15)  
DIALOG(R)File 15: ABI/Inform(R)  
(c) 2009 ProQuest Info&Learning. All rights reserved.

01905277 05-56269

**Health care incentives in immunisation**

Achat, Helen; McIntyre, Peter; Burgess, Margaret  
Australian & New Zealand Journal of Public Health v23n3 pp: 285-288  
Jun 1999  
**ISSN:** 1326-0200 **Journal Code:** AUP  
**Word Count:** 3681

**Text:**

...Although varying in costeffectiveness, both monetary and nonmonetary incentives can improve childhood immunisation uptake. Evaluation of current programs including the Australian ones will assist future **allocation**

of **resources**.

The successful use of incentives to influence behaviour and improve productivity has led to their application in the health arena. Incentives have been offered to...

...attractive to patients, or to offer increased earnings for identified behaviour.<sup>7-10</sup> Such performance-based incentives have influenced general practitioners' (GPs') practice patterns,<sup>o</sup> **allocation of resources**,<sup>11</sup> and behaviour indirectly related to health such as participation in postgraduate education<sup>12</sup> and response to postal surveys.<sup>13</sup>

This paper reviews the use of...the 1990 contract for general practitioners on night visiting. Br J Gen Pract 1994; 44: 68-71. 48. Skinner J, March L, Simpson JM. A **retrospective cohort** study of childhood immunisation status in northern Sydney. Aust J Public Health 1995; 9: 5863.  
Author Affiliation:

Helen Achat, Peter McIntyre and Margaret Burgess National...

---

4/3,K/14 (Item 2 from file: 148)  
DIALOG(R)File 148: Gale Group Trade & Industry DB  
(c) 2009 Gale/Cengage. All rights reserved.

15979263    **Supplier Number:** 103731431 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Length of stay, conditional length of stay, and prolonged stay in pediatric asthma. (Access in Chronic Care).(a study finds the overall management of asthma admissions appears more efficient in Pennsylvania than in New York)(Illustration)**

Silber, Jeffrey H.; Rosenbaum, Paul R.; Even-Shoshan, Orit; Shabbout, Mayadah; Zhang, Xuemei; Bradlow, Eric T.; Marsh, Roger R.  
Health Services Research , 38 , 3 , 867(20)  
June , 2003

**Document Type:** Illustration

ISSN: 0017-9124

**Language:** English

**Record Type:** Fulltext; Abstract

**Word Count:** 7080    **Line Count:** 00725

**Author Abstract:** ...the states of Pennsylvania and New York using claims data obtained from each state for the years 1996-1998, n = 38,310.

**Study Design.** A **retrospective cohort** design to model length of stay (LOS), the probability of prolonged stay, conditional length of stay (CLOS or the LOS after stay is prolonged), and...

**Text:**

...yes/no) indicating readmission within three weeks of discharge.

Each outcome describes different aspects of medical care. The

overall LOS provides insight into the overall **allocation** of **resources** by the provider. The prolonged stay variable describes the ability of providers to effectively treat and discharge the less complicated patient in a rapid manner...

---

4/3,K/15 (Item 3 from file: 148)  
DIALOG(R)File 148: Gale Group Trade & Industry DB  
(c) 2009 Gale/Cengage. All rights reserved.

15859425 **Supplier Number:** 102090745 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Health care costs among smokers, former smokers, and never smokers in an HMO.**

Fishman, Paul A.; Khan, Zeba M.; Thompson, Ella E.; Curry, Susan J.

Health Services Research , 38 , 2 , 733(17)

April , 2003

ISSN: 0017-9124

**Language:** English

**Record Type:** Fulltext; Abstract

**Word Count:** 5784 **Line Count:** 00534

**Author Abstract:** Objective. We estimate long-term health care costs of former smokers compared with continuing and never smokers using a **retrospective cohort** study of HMO enrollees. Previous research on health care costs associated with former smokers has suggested that quitters may incur greater health care costs than in western Washington state.

**Study Design.** **Retrospective cohort** study using automated and primary data collected through telephone interviews.

**Principal Findings.** We find that former smokers' costs are significantly greater ( $p < .05$ ) in the...

**Text:**

...because we assumed that they were unlikely to start smoking as adults.

Health Care Costs

Beginning in January 1990, GHC information systems capture and fully **allocate** health service **costs** for all internal services provided directly by GHC as well as for claims for covered services that enrollees receive from contracted providers (Fishman et al. 1997). To **allocate costs**, a **resource** intensity **weight** is assigned to each service, procedure, pharmacy fill, or diagnostic test provided by GHC or its contracted providers. The methodology for computing the **resource** intensity **weight** is unique to each cost center in the delivery system. ...margin is included in this allocation, but because GHC is organized as a nonprofit consumer-governed cooperative, these revenues are redistributed into the delivery system.

**Costs allocated** to GHC enrollees for services received from providers outside the GHC group model are GHC's payment to those providers. Although such ...typical year. Costs to non-GHC providers represent approximately 25 percent of total delivery system costs in a typical year (Fishman et al. 1997). The **cost allocation** system allows the identification of costs for specific encounters and services as well as aggregation of costs for individuals over ...truncated

cost data for subjects that disenrolled from GHC after December 1994.

An additional empirical challenge in estimating the model is caused by the skewed **distribution** of health care **costs**, which results in nonnormally distributed regression residuals that limit the use of standard linear regression methods for estimating the model. To address this challenge we (Madden, and Hornbrook 1999), regression residuals are modeled based on the gamma distribution, an approach that has been demonstrated as an appropriate **distribution** for health care **costs**. To assess the sensitivity of our results to this choice of empirical specification we also estimated the model using Generalized Estimating Equations (GEE).

We adjust...Nonvolunteer Smokers." Journal of Consulting and Clinical Psychology 63 (6): 1005-14.

Fishman, P., M. Von Korff, P. Lozano, and J. Hecht. 1997. "Chronic Care **Costs** in **Managed** Care." Health Affairs 16 (3): 239-47.

Gritz, E. R., C. R. Carr,

---

4/3,K/11 (Item 3 from file: 16)

DIALOG(R)File 16: Gale Group PROMT(R)

(c) 2009 Gale/Cengage. All rights reserved.

09731971 **Supplier Number: 84393211 (USE FORMAT 7 FOR FULLTEXT)**

**Diabetes-Related Morbidity and Mortality in a National Sample of U.S. Elders.  
(Epidemiology/Health Services/Psychosocial Research).**

Bertoni, Alain G.; Krop, Julie S.; Anderson, Gerard F.; Brancati, Frederick L.

Diabetes Care , v 25 , n 3 , p 471(5)

March , 2002

**Language:** English **Record Type:** Fulltext

**Document Type:** Magazine/Journal; Refereed ; Professional

**Word Count:** 4314

-

...is unclear. Better understanding of the burden of diabetes in the elderly might guide decisions about treatment and prevention at the individual level and about **allocation** of public health **resources** at the national level. Therefore, we sought to determine all-cause mortality rates and the incidence of serious diabetes-related complications in a nationally representative...Boyle DI, Ebrahim AR, Vasudev N, Stewart CP, Jung RT, Leese GP, MacDonald TM, Newton RW: Diabetes and lower-limb amputations in the community: a **retrospective cohort** study. Diabetes Care

---

4/3,K/12 (Item 4 from file: 16)

DIALOG(R)File 16: Gale Group PROMT(R)

(c) 2009 Gale/Cengage. All rights reserved.

08411299   **Supplier Number:** 69493727 (USE FORMAT 7 FOR FULLTEXT)

**Potential Short-Term Economic Benefits of Improved Glycemic Control: A managed care perspective.**

MENZIN, JOSEPH; LANGLEY-HAWTHORNE, CLARE; FRIEDMAN, MARK; BOULANGER, LUKE; CAVANAUGH, ROBERT

Diabetes Care , v 24 , n 1 , p 51

Jan , 2001

**Language:** English   **Record Type:** Fulltext

**Document Type:** Magazine/Journal; Refereed ; Professional

**Word Count:** 4990

**Supplier Number:** (USE FORMAT 7 FOR FULLTEXT)

**Text:**

...diabetes. The goal of this study was to examine the potential impact of improved glycemic control on selected short-term complications of diabetes and associated **costs** in a **managed** care setting.

RESEARCH DESIGN AND METHODS-- Using a **retrospective cohort** design and automated databases from 1 January 1994 to 30 June 1998, adult members of the Fallon Clinic who were diagnosed with diabetes were identified...

...diabetes, such as ischemic heart disease, kidney disease, or retinopathy, versus those without these complications?

RESEARCH AND DESIGN METHODS -- This study was based on a **retrospective cohort** design and used automated enrollment, medical and pharmacy claims, and clinical laboratory data files from the Fallon Clinic in Worcester, Massachusetts, a multispecialty group clinic...

**File 149:TGG Health&Wellness DB(SM) 1976-2009/May W5**

**(c) 2009 Gale/Cengage**

**File 444:New England Journal of Med. 1985-2009/Jun W3**

**(c) 2009 Mass. Med. Soc.**

**File 129:PHIND(Archival) 1980-2009/May W4**

**(c) 2009 Informa UK Ltd**

**File 130:PHIND(Daily & Current) 2009/Jun 30**

**(c) 2009 Informa UK Ltd**

12/3,K/9 (Item 9 from file: 149)	Set	Items	Description
S1	82181		(ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR DIVID?()UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?)(3N)(RESOURC? OR CAPITAL OR AVAILABLE()MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR)
S2	2		S1(12N)(S COHORT()TIME OR RETROSPECT?()COHORT? )
S3	1		S2 NOT PY>2003
S4	11099		(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N)(INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR REPAR? OR CORRECTION? OR CORRECTIV?)
S5	7538		(UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA()POINT? OR ENTITY OR ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N)(POPULATION OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO()OBSERV? OR TESTING OR TRIAL? OR STUDY OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)
S6	1133		PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR START?()("FROM" OR WITH)) (4N)(DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR (CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N)(DEFIN? OR DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR ARRIV?()AT OR ASSIGN?))
S7	1915		(PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT? OR RANGE?) OR TIMES OR DURATION OR DURING(2N)TERM OR LONG() (TERM OR RANGE) ) (4N)(AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W)(MARKET? OR CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)
S8	2358		(DURATION OR TIME? OR PERIOD? OR (AFTER OR "FROM") (2W)(START? OR COMMENC?) OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV? OR WINDOW?) (4N)(TREATMENT? OR INTERVENTION? OR THERAP? OR REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINISTRATION?)
S9	151		S5 AND S6 AND S7 AND S8
S10	50		S9(20N)S1
S11	36		S10 NOT PY>2003
S12	36		RD (unique items)

**DIALOG(R)File 149: TGG Health&Wellness DB(SM)**

**(c) 2009 Gale/Cengage. All rights reserved.**

02006852    **Supplier Number:** 76653435 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**A Collaborative Program for Cardiovascular Patient Follow-up.(Statistical Data Included)**

DEATON, CHRISTI; KURTZ, SHERRON; WEINTRAUB, WILLIAM S.

AORN Journal , 74 , 1 , 22

July ,

2001

**Document Type:** Statistical Data Included    **Publication Format:** Magazine/Journal

ISSN: 0001-2092

**Language:** English

**Record Type:** Fulltext; Abstract    **Target Audience:** Professional

**Word Count:** 4222    **Line Count:** 00404

...gastro-intestinal			
disturbance	1.3%	20%	1.4%
Sleep disturbance	7.5%	31%	21%
Leg problems	5%	4%	5.5%
Other	7%	10%	5.5%

**Patients**

frequently expressed more than one concern, so numbers do  
not add up to 100%; P < .001 for differences in the

**distribution**

of reported concerns.

**RESOURCE USE**

There were significant group differences in resource **use**  
during the 30-day **period** after undergoing cardiovascular procedures.  
The majority of patients (95%) saw a physician during this time and cited  
routine follow-up as the primary reason for...

---

12/3,K/14 (Item 14 from file: 149)  
DIALOG(R)File 149: TGG Health&Wellness DB(SM)  
(c) 2009 Gale/Cengage. All rights reserved.

01857034    **Supplier Number:** 19928331 (USE FORMAT 7 OR 9 FOR FULL TEXT )  
**Exploring the research base and outcome measures for portable bladder ultrasound technology.**

Wagner, Michele L.; Schmid, Marlene M.

MedSurg Nursing , v6 , n5 , p304(11)

Oct ,

1997

**Publication Format:** Magazine/Journal; Refereed

ISSN: 1092-0811

**Language:** English



**Record Type:** Fulltext; Abstract **Target Audience:** Professional

**Word Count:** 6559 **Line Count:** 00646

...enhancing patient and nurse satisfaction, and (e) cost savings for the patient and the institution. Cost savings are associated with reductions in catheter equipment, nursing **time**, and **treatment costs**.

The projected **budget** is variable. **Costs** vary depending on the model of BladderScan BVI technology and options selected. The projected budget should include initial and ongoing costs. Initial costs include: (a...

---

12/3,K/33 (Item 1 from file: 444)

DIALOG(R)File 444: New England Journal of Med.

(c) 2009 Mass. Med. Soc. All rights reserved.

00119956

Copyright 2000 by the Massachusetts Medical Society

### **Medical Progress: Unstable Angina Pectoris (Review Article)**

Yeghiazarians, Yerem; Braunstein, Joel B.; Askari, Arman; Stone, Peter H.

The New England Journal of Medicine

Jan 13 , 2000 ; 342 (2),pp 101-114

**Line Count:** 00756 **Word Count:** 10436

#### **Text:**

...be at low risk may be suitable for continued medical management. Use of an early, reliable risk-stratification process may permit the appropriate and economical **allocation** of medical **resources** and the optimal outcomes for **patients**.

---

12/3,K/15 (Item 15 from file: 149)

DIALOG(R)File 149: TGG Health&Wellness DB(SM)

(c) 2009 Gale/Cengage. All rights reserved.

01815946 **Supplier Number:** 53621977 (USE FORMAT 7 OR 9 FOR FULL TEXT )

**Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms.**

Forbes, J. F.

The Lancet , 352 , 9141 , 1656(1)

Nov 21 ,

1998

**Publication Format:** Magazine/Journal; Refereed

ISSN: 0099-5355

**Language:** English

**Record Type:** Fulltext; Abstract **Target Audience:** Professional

**Word Count:** 4588 **Line Count:** 00387

...day case ((British pounds) 369) and attendance at outpatient clinics ((British pounds) 55) were calculated from unit costs reported from a national system of hospital **cost** statistics,<sup>11</sup> **weighted** by the number of **patients** randomised in the trial centres in Scotland (187 of 1090). The cost of attendance at outpatient clinics for routine ultrasonographic surveillance ((British pounds) 84) was...

...item recoding, treatment of missing items, and scoring.

Statistical analysis

We analysed health service costs and quality of life by intention to treat. The cumulative **cost distribution** arising from ultrasonographic surveillance, aneurysm repair, and the use of other health services was summarised by mean costs **observed** for all **patients** in accordance with the full-sample method, with no adjustment for censored cases.<sup>15</sup> **Distribution** of surveillance **costs** was measured from randomisation until aneurysm repair and from randomisation until the last recorded follow-up visit for **patients** under surveillance. We included aneurysm repair costs in the cumulative **cost distribution**, irrespective of the timing of surgical repair during follow-up. Information on the use of other health services, not directly related to the surgical management...

---

12/3,K/34 (Item 2 from file: 444)

DIALOG(R)File 444: New England Journal of Med.

(c) 2009 Mass. Med. Soc. All rights reserved.

00102941

Copyright 1987 by the Massachusetts Medical Society

### **Decreasing Risk Of Leukemia With Prolonged Follow-up After Chemotherapy And Radiotherapy For Hodgkin's Disease (Original Article)**

Blayney, Douglas W.; Longo, Dan L.; Young, Robert C.; Greene, Mark H.; Hubbard, Susan M., R.N.; Postal, Marcia G., R.N., M.S.; Duffey, Patricia L., R.N.; DeVita, Vincent T., Jr.

The New England Journal of Medicine

March 19 , 1987 ; 316 (12),pp 710-714

**Line Count:** 00336 **Word Count:** 04639

#### **Text:**

...events occurred at the same time after the start of observation. An estimated risk function was computed, expressing the risk of an event per total **person-years** of **observation** during each interval.

The estimated **value** of the **risk** function was used in a multiple linear regression analysis. The natural logarithm of the estimated risk was selected as the dependent variable, and time and...

#### **IV. Text Search Results from Dialog (Abstract dbs)**

##### **A. Abstract Databases -- Patent**

**File 347:JAPIO Dec 1976-2009/Jan(Updated 090503)**

**(c) 2009 JPO & JAPIO**

**File 350:Derwent WPIX 1963-2009/UD=200939**

**(c) 2009 Thomson Reuters**

Set	Items	Description
S1	106273	(ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT OR DEVOT? OR DIVID?())UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?) (3N) (RESOURC? OR CAPITAL OR AVAILABLE())MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR)
S2	1708	(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N) (INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR REPAR? OR CORRECTION? OR CORRECTIV?)
S3	0	COHORT()TIME OR RETROSPECT?()COHORT?
S4	260	S1(12N)S2
S5	1	S4 AND COHORT?
S6	102	(UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA()POINT? OR ENTITY OR ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N) (POPULATION OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO()OBSERV? OR TESTING OR TRIAL? OR STUDY OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)
S7	34	(PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR START?() (" (4N) (DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR (CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N) (DEFIN? OR DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR ARRIV?()AT OR ASSIGN?)) FROM" OR WITH))
S8	29	(PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT? OR RANGE?) OR TIMES OR DURATION OR DURING(2N)TERM OR LONG() (TERM OR RANGE) ) (4N) (AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W) (MARKET? OR CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)
S9	104	(DURATION OR TIME? OR PERIOD? OR (AFTER OR " (2W) (START? OR COMMENC?) OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV? OR WINDOW?) (4N) (TREATMENT? OR INTERVENTION? OR THERAP? OR REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINISTRATION?) FROM")
S10	237	S6 OR S7 OR S8 OR S9
S11	236	S10 NOT S5
S12	122	S11 NOT AY>2003
S13	21	S12(20N)S1
S14	21	IDPAT (sorted in duplicate/non-duplicate order)
S15	21	IDPAT (primary/non-duplicate records only)

15/3,K/16 (Item 16 from file: 350)  
 DIALOG(R)File 350: Derwent WPIX  
 (c) 2009 Thomson Reuters. All rights reserved.  
 0009798447 *Drawing available*  
 WPI Acc no: 2000-087630/200008  
 Related WPI Acc No: 1998-251718  
 XRAM Acc no: C2000-024507  
 XRPX Acc No: N2000-068882

**Computer implement disease and condition management for at-risk patient intervention**

Patent Assignee: SMITHKLINE BEECHAM CORP (SMIK)

Inventor: BOYKO D A; GALLO E F; LANGER D; PRESS B; STAVRAKAS S; WONG B J O

Patent Family ( 2 patents, 1 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
AU 199953551	A	19991202	AU 199739307	A	19970929	200008	B
			AU 199953551	A	19991008		
AU 727263	B	20001207	AU 199739307	A	19970929	200103	E
			AU 199953551	A	19991008		

Priority Applications (no., kind, date): US 199627074 P 19960930

Patent Details						
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
AU 199953551	A	EN	71	13	Division of application	AU 199739307
AU 727263	B	EN			Division of application	AU 199739307
					Previously issued patent	AU 9953551

**Alerting Abstract ...ADVANTAGE** - Using the intervention **management** system provides a **cost** effective method that uses the best up to date medical practices available. If **patients** are treated with therapy regimens that have proven effective for other patients with the same disease then the number of cases and cost of each...

---

**Dialog eLink:** [Order File History](#)

15/3,K/9 (Item 9 from file: 350)  
 DIALOG(R)File 350: Derwent WPIX  
 (c) 2009 Thomson Reuters. All rights reserved.

0010741911 *Drawing available*  
 WPI Acc no: 2001-354523/200137  
 XRPX Acc No: N2001-257596

**Computer-based system has computer executable instruction for projecting cost and benefits**

**linked to disease management intervention over predetermined period based on received population specific data**

Patent Assignee: GLAXO GROUP LTD (GLAX)

Inventor: HALPERN M T; KHAN Z M; KHAN Z M G W I; OLSON P S; OLSON P S G W I; YOUNG T L; YOUNG T L G W I

Patent Family ( 4 patents, 93 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2001009758	A2	20010208	WO 2000US21106	A	20000802	200137	B
AU 200063971	A	20010219	AU 200063971	A	20000802	200137	E
EP 1198755	A2	20020424	EP 2000950944	A	20000802	200235	E
			WO 2000US21106	A	20000802		
JP 2003522994	W	20030729	WO 2000US21106	A	20000802	200358	E
			JP 2001514696	A	20000802		

Priority Applications (no., kind, date): US 1999366007 A 19990802

Patent Details						
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
WO 2001009758	A2	EN	90	14		
National Designated States,Original	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Regional Designated States,Original	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
AU 200063971	A	EN			Based on OPI patent	WO 2001009758
EP 1198755	A2	EN			PCT Application	WO 2000US21106
					Based on OPI patent	WO 2001009758
Regional Designated States,Original	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2003522994	W	JA	86		PCT Application	WO 2000US21106
					Based on OPI patent	WO 2001009758

Original Publication Data by AuthorityArgentina**Publication No. ...Original Abstracts:**provide a graphical user interface through which a user inputs population-specific data for a population to be treated or offered treatment in a disease **management** intervention. **Costs** and **benefits** associated **with** the disease **management** intervention are projected over **a time period** for the **population** based on the

user-specified data. The costs and benefits are output to the user to facilitate evaluation of the economic impact of the disease... ... provide a graphical user interface through which a user inputs population-specific data for a population to be treated or offered treatment in a disease **management** intervention. **Costs** and benefits associated with the disease **management** intervention **are** projected over a **time period** for the **population** based on the user-specified data. The costs and benefits are output to the user to facilitate evaluation of the economic impact of the disease management intervention...

---

**Dialog eLink:** [Order File History](#)

15/3,K/4 (Item 4 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0013463867 *Drawing available*

WPI Acc no: 2003-555387/200352

XRAM Acc no: C2003-149929

XRPX Acc No: N2003-441102

**Data processing system for implementing program controlled management of physician-patient interactions, comprises workstation programs for providing patient history, data base server and communication server**

Patent Assignee: SOLL A H (SOLL-I); SOLL L V (SOLL-I)

Inventor: SOLL A H; SOLL L V

Patent Family ( 1 patents, 1 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20030055679	A1	20030320	US 1999289044	A	19990409	200352	B

Priority Applications (no., kind, date): US 1999289044 A 19990409

Patent Details					
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes
US 20030055679	A1	EN	49	13	

**Alerting Abstract** ... and potential diagnosis; a database server for accessing the workstation programs, to form a local area network for storing medical information related to number of **patients** and is adapted to **manage** the **cost** of medical **care**, utilization of one or **more** physicians, **laboratory** data, indication, reference data, surgery data and/or pathology data; and a communication server adapted for connecting to the Internet, hospital computer network and/or...

---

**Dialog eLink:** [Order File History](#)

15/3,K/10 (Item 10 from file: 350)

0010460992 *Drawing available*  
WPI Acc no: 2001-060511/200107  
XRPX Acc No: N2001-045308

**Treatment determining method for patient through network, involves computing risk value indicating likelihood of patient from developing disease and adjusting computed risk value**

Patent Assignee: DENTAL MEDICINE INT LLC (DENT-N)

Inventor: MARTIN J; MARTIN J A; NOLF R; NOLF R R

Patent Family ( 5 patents, 88 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2000057310	A1	20000928	WO 2000US7712	A	20000323	200107	B
AU 200039127	A	20001009	AU 200039127	A	20000323	200108	E
US 20020004725	A1	20020110	US 1999125931	P	19990323	200208	E
			US 1999396404	A	19990915		
US 6484144	B2	20021119	US 1999125931	P	19990323	200280	E
			US 1999396404	A	19990915		
US 20030154109	A1	20030814	US 1999125931	P	19990323	200355	E
			US 1999396404	A	19990915		
			US 2002289711	A	20021107		

Priority Applications (no., kind, date): US 1999125931 P 19990323; US 1999396404 A 19990915; US 2002289711 A 20021107

Patent Details of application					US 1999396404
Patent Number	Kind	Lan	Pgs	Draw	Division of patent Filing Notes
WO 2000057310	A1	EN	36	7	US 6484144
National Designated States,Original	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW				
Regional Designated States,Original	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW				
AU 200039127	A	EN			Based on OPI patent WO 2000057310
US 20020004725	A1	EN			Related to Provisional US 1999125931
US 6484144	B2	EN			Related to Provisional US 1999125931
US 20030154109	A1	EN			Related to Provisional US 1999125931



Original Publication Data by AuthorityArgentina**Publication No. ...Original Abstracts:**provider. The outcomes (208) associated with treatment and risk assessment are fed back into the healthcare system to increase its accuracy and subsequent effectiveness in **computing risk values over time**.

**Dialog eLink:** [Order File History](#)

15/3,K/17 (Item 17 from file: 350)

DIALOG(R)File 350: Derwent WPIX

(c) 2009 Thomson Reuters. All rights reserved.

0009027144 *Drawing available*

WPI Acc no: 1998-584091/199850

XRPX Acc No: N1998-455218

**Surgical Instrument Management System e.g. for individual identification of surgical instruments - has process control program to generate stencils which are used to permanently mark each individual surgical instrument with non acid based etch to show unique identification number, tray name with data logged onto computer**

Patent Assignee: SYSTEMS INFORMATION TECHNOLOGIES PTY LTD (SYST-N); TOOL & INSTR ENG PTY LTD (TOOL-N)

Inventor: OSBORNE G; OSBORNE P; STANTON M

Patent Family ( 3 patents, 20 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
AU 697140	B	19980924	AU 199871932	A	19980618	199850	B
WO 1999066444	A1	19991223	WO 1999AU492	A	19990618	200007	E
AU 199944911	A	20000105	AU 199944911	A	19990618	200024	E

Priority Applications (no., kind, date): AU 199871932 A 19980618

Patent Details						
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
AU 697140	B	EN	6	1		
WO 1999066444	A1	EN				
National Designated States,Original	AU US					
Regional Designated States,Original	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
AU 199944911	A	EN			Based on OPI patent	WO 1999066444

**Alerting Abstract ...**The Surgical Instrument Management provides the only method of direct **allocation** of surgical costs to **individual patients**.

?

5/3,K/1 (Item 1 from file: 350)  
 DIALOG(R)File 350: Derwent WPIX  
 (c) 2009 Thomson Reuters. All rights reserved.

0014179605

WPI Acc no: 2004-364874/200434

XRAM Acc no: C2004-137749

XRPX Acc No: N2004-291838

**Set of probes for detecting relevant variants in target genes relating to adverse events, comprises nucleotide probes complementary to DNA and RNA sequences of genes such as apolipoprotein E gene, or angiotensinogen gene**

Patent Assignee: SCIONA LTD (SCIO-N)

Inventor: GRIMALDI K; ROBERTS G W

Patent Family ( 3 patents, 104 countries )							
Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2004033722	A2	20040422	WO 2003GB4051	A	20030923	200434	B
AU 2003269159	A1	20040504	AU 2003269159	A	20030923	200465	E
AU 2003269159	A8	20051103	AU 2003269159	A	20030923	200629	E

Priority Applications (no., kind, date): GB 200222042 A 20020923

AU 2003269159	A8	EN		Patent Details	Based on OPI patent	WO 2004033722
Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
WO 2004033722	A2	EN	68	0		
National Designated States,Original	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
Regional Designated States,Original	AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
AU 2003269159	A1	EN			Based on OPI patent	WO 2004033722

**Alerting Abstract** ... general health screening, occupational health purposes, health care planning on a population basis, and other health care management utilizations. (I) or (II) is useful for **development** of new strategies **of therapeutic intervention** and in clinical **trials**, construction of and generation of algorithms for patient and health care management, and for modeling or assessing the impact of diseases or health care management strategies on individuals, groups, patient **cohorts** or populations. (I) or (II) is useful for modeling, assessing or **exploring** the theoretical impact of diseases and health care management strategies on individuals, groups, patient **cohorts** or populations. (I) or (II) is useful for predicting optimum configuration/**management** of therapeutic intervention, identifying of gene variants, which is an indicative of a higher risk of experiencing adverse events for the patient

## B. Abstract Databases – NON-PATENT

**File 35:Dissertation Abs Online 1861-2009/Jun**  
(c) 2009 ProQuest Info&Learning

**File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13**  
(c) 2002 Gale/Cengage

**File 65:Inside Conferences 1993-2009/Jun 30**  
(c) 2009 BLDSC all rts. reserv.

**File 2:INSPEC 1898-2009/Jun W3**  
(c) 2009 The IET

**File 474:New York Times Abs 1969-2009/Jul 01**  
(c) 2009 The New York Times

**File 475:Wall Street Journal Abs 1973-2009/Jul 01**  
(c) 2009 The New York Times

**File 99:Wilson Appl. Sci & Tech Abs 1983-2009/May**  
(c) 2009 The HW Wilson Co.

**File 256:TecTrends 1982-2009/Jun**  
(c)2009 Info.Sources Inc.All rights reserved

**File 5:Biosis Previews(R) 1926-2009/Jun W3**  
(c) 2009 The Thomson Corporation

**File 73:EMBASE 1974-2009/Jun 29**  
(c) 2009 Elsevier B.V.

**File 155:MEDLINE(R) 1950-2009/Jun 29**  
(c) format only 2009 Dialog

**File 34:SciSearch(R) Cited Ref Sci 1990-2009/Jun W3**  
(c) 2009 The Thomson Corp

**File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec**  
(c) 2006 The Thomson Corp

**File 74:Int.Pharm.Abs 1970-2009/Mar B2**  
(c) 2009 The Thomson Corporation

**File 42:Pharm. News Index 1974-2009/May W5**  
(c) 2009 ProQuest Info&Learning

Set	Items	Description
S1	973029	(ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR DIVID?())UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?)(3N)(RESOURC? OR CAPITAL OR AVAILABLE())MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W)RISK OR VAR)
S2	23262	(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N)(INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTHCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR REPAR? OR CORRECTION? OR CORRECTIV?)
S3	76	COHORT()TIME OR RETROSPECT?()COHORT?

S4 35 S3 NOT PY>2003  
 S5 22 RD (unique items)  
 S6 0 COHORT()TIME  
 S7 139 COHORT()TIME  
 S8 82 RD (unique items)  
 S9 44 S8 NOT PY>2003  
 S10 1 S5(12N)S1  
 S11 10520 (UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA()POINT? OR ENTITY OR ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N)(POPULATION OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO()OBSERV? OR TESTING OR TRIAL? OR STUDY OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)  
 S12 631 (PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR START?() ("FROM" OR WITH)) (4N) (DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR (CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N) (DEFIN? OR DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR ARRIV?()AT OR ASSIGN?))  
 S13 649 (PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT? OR RANGE?) OR TIMES OR DURATION OR DURING(2N)TERM OR LONG() (TERM OR RANGE) ) (4N) (AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W) (MARKET? OR CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)  
 S14 2175 (DURATION OR TIME? OR PERIOD? OR (AFTER OR "FROM") (2W) (START? OR COMMENC?) OR FOLLOWING OR SUBSEQUENT()TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV? OR WINDOW?) (4N) (TREATMENT? OR INTERVENTION? OR THERAP? OR REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINIST?)  
 S15 4 S11 AND S12 AND S13 AND S14

9/5,K/14 (Item 10 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14522954 **Biosis No.:** 199800317201

# **Evaluation of mortality factors and risk analysis for the design of an integrated pest management system**

**Author:** Roux Olivier (Reprint); Baumgartner Johann

**Author Address:** Swiss Federal Office Agriculture, Mattenhofstr. 5, CH-3003 Bern, Switzerland\*\*Switzerland

**Journal:** Ecological Modelling 109 ( 1 ): p 61-75 June 1, 1998 1998

**Medium:** print

**ISSN:** 0304-3800

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** A probabilistic approach of survival analysis based on the theory of competing risks was applied to the potato tuber moth *Phthorimaea operculella* (Zeller) affecting tubers in Tunisian rustic stores. Exponential curve of death. i.e., constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors. which permits to judge different control strategies. In an integrated pest management perspective, the effect of basic mortalities, i.e., innate and dispersal related mortalities is recombined with native natural

enemies. Thereafter, we calculate the force of additional compatible control factors needed to reduce the proportion of infested tubers below an economically relevant level. Control strategies based on native natural enemies are shown to have variable effects which put farmers at economic risks. The general importance of integrating compatible control factors is recognized in the evaluation of virus applications. Based on risk analyses. Tunisian potato growers were recommended, in the case of standard initial infestations of five eggs per tuber, to use virus preparations at a higher dosage than the 0.0015 larval equivalent kg as used in this study. Moreover, the study confirms the general importance of entering potatoes with low infestation levels into rustic shelters. This considerably decreases the risk of exceeding the economic threshold and make virus based control efficient even at low dosages. If the initial infestation considerably exceeds five eggs per tuber, the integration of a compatible control factor becomes more difficult. Nevertheless, even in absence of additional control factors the infestation of tubers does not exceed 50%.

#### **DESCRIPTORS:**

**Major Concepts:** Mathematical Biology--Computational Biology; Pest Assessment Control and Management

**Biosystematic Names:** Lepidoptera--Insecta, Arthropoda, Invertebrata, Animalia; Solanaceae-- Dicotyledones, Angiospermae, Spermatophyta, Plantae

**Organisms:** Phthorimaea operculella {potato tuber moth} (Lepidoptera)--storage pest; potato (Solanaceae)--crop

**Common Taxonomic Terms:** Animals; Arthropods; Insects; Invertebrates; Angiosperms; Dicots; Plants; Spermatophytes; Vascular Plants

**Geographical Name:** Tunisia (Palearctic region)

**Miscellaneous Terms: Concept Codes:** competing risks; economics; hazard rate functions; integrated pest management; mortality factors; survival analysis

#### **Concept Codes:**

60015 Economic entomology - Integrated control

05500 Social biology and human ecology

12510 Pathology - Necrosis

54600 Pest control: general, pesticides and herbicides

60008 Economic entomology - Stored products

64076 Invertebrata: comparative, experimental morphology, physiology and pathology - Insecta: physiology

#### **Biosystematic Codes:**

75330 Lepidoptera

26775 Solanaceae

**Abstract:** ...affecting tubers in Tunisian rustic stores. Exponential curve of death. i.e., constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors. which permits to judge different control strategies. In...

10/5,K/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

14377618 **Biosis No.:** 199800171865

**Cost-identification analysis in oral cavity cancer management**

**Author:** Funk Gerry F (Reprint); Hoffman Henry T; Karnell Lucy Hynds; Ricks Joan M; Zimmerman M Bridget; Corbae Dean P; Hussey David H; McCulloch Timothy M; Graham Scott M; Dawson Cindy J; Means Mary E; Colwill Margaret L; Titler Marita G; Smith Elaine M

**Author Address:** Dep. Otolaryngol.-Head Neck Surg., 200 Hawkins Dr., Room E230GH, Univ. Iowa Hosp. Clin., Iowa City, IA 52242, USA\*\*USA

**Journal:** Otolaryngology - Head and Neck Surgery 118 ( 2 ): p 211-220 Feb., 1998 1998

**Medium:** print

**ISSN:** 0194-5998

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Abstract:** The objectives of this study were to investigate potential relationships between pretreatment patient-mix characteristics, treatment modalities, and costs generated during the pretreatment work-up, treatment, and 1-year follow-up periods for patients with oral cavity cancer (OCC). Another objective was to identify potential areas for cost reduction and improved **resource allocation** in the **management** of OCC patients. Using a **retrospective cohort** of 73 patients with OCC, pretreatment patient-mix characteristics and treatment modalities were evaluated in relation to university-based charges incurred during the pretreatment evaluation, treatment, and 1-year follow-up periods. Simple regression and stepwise multiple regression analyses were used to develop predictive models for cost based on independent variables, including age, AJCC TNM clinical stage, smoking history, American Society of Anesthesiologists (ASA) class, comorbidity as defined by the Kaplan-Feinstein grade and treatment modality. The dependent measurements included all physician, office, and hospital charges incurred at the University of Iowa Hospitals and Clinics during the pretreatment evaluation, treatment, and follow-up periods, as well as the total pretreatment through 1-year follow-up management costs. Independent variables that were identified as being significantly associated with treatment costs included T classification, N classification, TNM stage, unimodality versus multimodality treatment, and the Kaplan-Feinstein comorbidity grade. Age, smoking status, and ASA class were not significantly associated with costs. The majority of the OCC management costs were incurred during the treatment period. The most substantial decreases in management costs for OCC will be realized through measures that allow identification and treatment of disease at an early stage, in which single-modality treatment may effectively be used. Resource allocation for OCC should support the investigation of measures through which the diagnosis and treatment of OCC at the earliest possible stage is facilitated. The presence of comorbid illness is a significant component in the determination of management costs for OCC and should be included in analyses of resource allocation for OCC. The singular diagnosis of OCC encompasses a wide range of patient illness severity, and diagnosis-related reimbursement schemes for OCC treatment should optimally differentiate between early and advanced stage disease.

**DESCRIPTORS:**

**Major Concepts:** Dental Medicine--Human Medicine, Medical Sciences; Oncology--Human Medicine, Medical Sciences; Public Health--Allied Medical Sciences

**Biosystematic Names:** Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

**Organisms:** human (Hominidae)--patient

**Common Taxonomic Terms:** Animals; Chordates; Humans; Mammals; Primates; Vertebrates

**Diseases:** oral cavity cancer

**Mesh Terms:** Mouth Neoplasms (MeSH)

**Miscellaneous Terms: Concept Codes:** cost reduction; diagnosis-related reimbursement scheme; illness severity; pretreatment patient-mix characteristics; resource allocation

**Concept Codes:**

37010 Public health - Public health administration and statistics

12504 Pathology - Diagnostic

19006 Dental - Pathology

24004 Neoplasms - Pathology, clinical aspects and systemic effects

37012 Public health - Health services and medical care

**Biosystematic Codes:**

86215 Hominidae

**Abstract:** ...and 1-year follow-up periods for patients with oral cavity cancer (OCC). Another objective was to identify potential areas for cost reduction and improved **resource allocation** in the **management** of OCC patients. Using a **retrospective cohort** of 73 patients with OCC, pretreatment patient-mix characteristics and treatment modalities were evaluated in relation to university-based charges incurred during the pretreatment evaluation...

15/3,K/3 (Item 2 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2009 Dialog. All rights reserved.

12869186 **PMID:** 9634053

**Managing many patients with a urethral stricture: a cost-benefit analysis of treatment options.**

Ogbonna B C

Department of Surgery, Jos University Teaching Hospital, Nigeria.

British journal of urology ( ENGLAND ) May 1998 , 81 (5) p741-4 , **ISSN:** 0007-1331--Print

**Journal Code:** 15740090R

Publishing Model Print

**Document type:** Journal Article; Research Support, Non-U.S. Gov't

**Languages:** ENGLISH

**Main Citation Owner:** NLM

**Record type:** MEDLINE; Completed

**Managing many patients with a urethral stricture: a cost-benefit analysis of treatment options.**

**OBJECTIVES:** To report a management method in a community where there are many **patients** with urethral stricture and where the short-term goal of providing some treatment to most may override the sometimes conflicting long-term aim of minimizing recurrence rates. **PATIENTS AND METHODS:** Over a 3-year period, using optical urethrotomy in 76 **patients** followed by intermittent self-dilatation (ISD) in 29, urethroplasty in 28 and dilatation in three, 92 of 134 **patients** with a urethral stricture were treated and the outcome compared. **RESULTS:** The overall recurrence rate was 22%; a combination of urethrotomy plus ISD had a... ..significantly increased both the time before recurrence and the duration



of follow-up without recurrence after urethrotomy. In addition to providing lasting treatment to many **patients**, urethrotomy was also 10 times cheaper, 10 times faster to perform and offered the surgeon better protection from infection with human immunodeficiency virus than did urethroplasty.

**CONCLUSION:** Because wrongly selecting urethrotomy (resulting in a **failed** procedure) wastes valuable operating **time** and resources, the pre-operative recognition of strictures unsuitable for urethrotomy and their treatment by urethroplasty is important for overall efficiency. (

**Descriptors:** ; Adolescent; Adult; Aged; Aged, 80 and over; Child; Cost-Benefit Analysis; Decision Making; Follow-Up Studies; Humans; Medical Audit; Middle Aged; Nigeria; **Prospective** Studies; Recurrence; **Treatment Failure**; Urethral Stricture--economics--EC; Urethral Stricture --etiology--ET; Urinary Catheterization

**Named Person:**

**File 8: Ei Compendex(R) 1884-2009/Jun W3**

**(c) 2009 Elsevier Eng. Info. Inc.**

**File 6: NTIS 1964-2009/Jul W1**

**(c) 2009 NTIS, Intl Cpyrght All Rights Res**

**File 34: SciSearch(R) Cited Ref Sci 1990-2009/Jun W3**

**(c) 2009 The Thomson Corp**

**File 7: Social SciSearch(R) 1972-2009/Jun W3**

**(c) 2009 The Thomson Corp**

**File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec**

**(c) 2006 The Thomson Corp**

Set	Items	Description
S1	75	COHORT() TIME
S2	69	RD (unique items)
S3	34	S2 NOT PY>2003
S4	483277	(ALLOCAT? OR SPEND? OR APPLY? OR DISTRIBUT? OR WEIGHT? OR DEVOT? OR DIVID?()UP OR MANAG? OR BUDGET? OR DECID? OR DECISION?) (3N) (RESOURC? OR CAPITAL OR AVAILABLE() MEANS OR COST? ? OR SUPPLY OR SUPPLIES OR MATERIEL OR BUDGET? OR DEVELOPMENT) OR (VALUE? ?(2W) RISK OR VAR)
S5	6528	(EFFECTIV? OR SUCCESS? OR UTILITY OR USEFUL? OR VALUE OR WORTH? OR BENEFI? OR ADVANTAGE? OR GAIN? ?) (4N) (INTERVENTION? OR TREATMENT? OR DIAGNOS? OR THERAP? OR HEALTCARE OR SURGER? OR SURGICAL OR DRUG OR PHARMACEUT? OR FIX? OR CURE? OR REPAIR? OR REPAR? OR CORRECTION? OR CORRECTIV?)
S6	2369	(UNIT? ? OR MEMBER? ? OR DATAPOINT? OR DATA() POINT? OR ENTITY OR ENTITIES OR INDIVIDUAL? ? OR PERSON? ? OR SUBJECT? ? OR PATIENT? ?) (2N) (POPULATION OR SAMPLE? OR OBSERVED OR OBSERVATION OR TO() OBSERV? OR TESTING OR TRIAL? OR STUDY OR STUDIES OR PATIENTS? ? OR COHORT? ? OR ANALYSIS)
S7	144	(PROSPECTIV? OR RETROSPECTIV? OR TIME? ? OR AFTER OR FOLLOWING OR SUBSEQUENT() TO OR SINCE OR START?() ("FROM" OR WITH)) (4N) (DIAGNOS? OR PROGNOS? OR FAIL? OR DEFECT? OR (CONDITION OR STATUS OR TYPE OR CATEGOR???) (2N) (DEFIN? OR DETERMIN? OR ASCERTAIN? OR LABEL? OR DESIGNAT? OR ARRIV?() AT OR ASSIGN?))
S8	192	(PERIOD? ? OR YEAR? ? OR ERA OR ERAS OR HISTOR? OR TIME() (SEGMENT? OR RANGE?) OR TIMES OR DURATION OR DURING(2N) TERM OR LONG() (TERM OR RANGE)

) (4N) (AUTHORIZ? OR USE OR USAGE OR AVAILABL? OR (IN OR ON OR POST) (2W) (MARKET? OR CIRCULATION) OR PRESCRIBAB? OR MARKETING OR USING OR MARKETPLACE)  
S9 514 (DURATION OR TIME? OR PERIOD? OR (AFTER OR "FROM") (2W) (START? OR COMMENC?) OR FOLLOWING OR SUBSEQUENT() TO OR SINCE OR PROSPECTIV? OR RETROSPECTIV? OR WINDOW?) (4N) (TREATMENT? OR INTERVENTION? OR THERAP? OR REPAIR? OR CORRECTION? OR CORRECTIV? OR ADMINIST?)  
S10 2510 S6 OR S7 OR S8  
S11 2735 S10 OR S9  
S12 621 S11 (12N) S4  
S13 168 S12 (7N) S5  
S14 84 S13 NOT PY>2003  
S15 76 RD (unique items)  
S16 0 (META() ANALY? (12N) HISTOR?) (S) S1

3/5,K/31 (Item 2 from file: 7)  
DIALOG(R)File 7: Social SciSearch(R)  
(c) 2009 The Thomson Corp. All rights reserved.

02989709 **Genuine Article#:** VZ990 **Number of References:** 67

**Title:** Twentieth-century family life cycle and its determinants in the United States

**Author(s):** ElKhorazaty MN

**Corporate Source:** RES TRIANGLE INST, ROCKVILLE MARYLAND OFF, POB 12194/RES TRIANGLE PK//NC/27709 (REPRINT)

**Journal:** JOURNAL OF FAMILY HISTORY , 1997 , V 22 , N1 , P 70-109

**Publisher:** SAGE PUBLICATIONS INC , 2455 TELLER RD, THOUSAND OAKS, CA 91320

**ISSN:** 0363-1990

**Language:** English **Document Type:** Article

**Subfile:** CC SOCS--Current Contents, Social & Behavioral Sciences

**Journal Subject Category:** ANTHROPOLOGY; FAMILY STUDIES

**Abstract:** Fertility schedules, one of the most important vital statistics, are used to construct a new period and **cohort time** series macrolevel data set of family life cycle/childbearing and fertility-inhibiting indices for the United States in the twentieth century. Calculation of these macrolevel indices on an annual basis is accomplished by the application of recent demographic methodologies, which require only knowledge of age-specific fertility rates. These annual sets of indices, which otherwise would require detailed biographical information on the dates of such events, are needed to fully capture demographic change and to quantitatively ascertain changes in fertility behavior and attitudes and hence, describe family structure and the timing and speed of child production for better understanding of American society.

**Identifiers--** KeyWord Plus(R): AMERICAN FAMILIES; FERTILITY

**Cited References:**

**Abstract:** Fertility schedules, one of the most important vital statistics, are used to construct a new period and **cohort time** series macrolevel data set of family life cycle/childbearing and fertility-inhibiting indices for the United States in the twentieth century. Calculation of these macrolevel...

**Identifiers--**

3/5,K/21 (Item 21 from file: 34)  
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.

05909809 **Genuine Article#:** XG075 **Number of References:** 55

**Time series analysis supporting the hypothesis that enhanced cosmic radiation during germ cell formation can increase breast cancer mortality in germ cell cohorts**

**Author:** Juckett DA (REPRINT) ; Rosenberg B

**Corporate Source:** BARROS RES INST,2430 COLL RD/HOLT//MI/48842 (REPRINT); MICHIGAN STATE UNIV,DEPT CHEM/E LANSING//MI/48824

**Journal:** INTERNATIONAL JOURNAL OF BIOMETEOROLOGY , 1997 , V 40 , N4 ( JUN ) , P 206-221

**ISSN:** 0020-7128 **Publication date:** 19970600

**Publisher:** SPRINGER VERLAG , 175 FIFTH AVE, NEW YORK, NY 10010

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA

**Subfile:** CC AGRI--Current Contents, Agriculture, Biology & Environmental Sciences

**Journal Subject Category:** BIOPHYSICS; METEOROLOGY & ATMOSPHERIC SCIENCES; ENVIRONMENTAL SCIENCES; PHYSIOLOGY

**Abstract:** Techniques from cancer epidemiology and time series analysis were used to explore the hypothesis that cosmic radiation can induce germ cell changes leading to increases in future breast cancer mortality. A birth **cohort time** series for female breast cancer mortality was obtained using a model-independent, age-period-cohort analysis on age-specific mortality data for 1940-1990. The birth cohort series contained several oscillatory components, which were isolated and compared to the corresponding frequency components of a cosmic ray surrogate time series - Greenland ice-core Be-10 concentrations. A technique, referred to as component wavetrain alignment, was used to show that the breast cancer and cosmic ray oscillations were phase-locked approx. 25 years before the time of birth. This is consistent with the time of germ cell formation, which occurs during the fetal development stage of the preceding generation. Evidence is presented that the observable oscillations in the birth cohort series were residues of oscillations of much larger amplitude in the germ cell cohort, which were attenuated by the effect of the broad maternal age distribution. It is predicted that a minimum of 50% of breast cancer risk is associated with germ cell damage by cosmic radiation (priming event), which leads to the development of individuals with a higher risk of breast cancer. It is proposed that the priming event, by preceding other steps of carcinogenesis, works in concert with risk factor exposure during life. The priming event is consistent with epigenetic changes such as imprinting.

**Descriptors--**Author Keywords: cosmic rays ; cancer ; time series ; age-period-cohort analysis ; epigenetic

**Identifiers--** KeyWord Plus(R): 11-YEAR CYCLE; AGE-PERIOD; TEMPORAL VARIATION; SOLAR-ACTIVITY; UNITED-STATES; HUMAN BIRTHS; FEMALE MICE; OSCILLATIONS; RATES; INFLUENZA

**Research Fronts:** 95-1802 001 (SOLAR-WIND TERMINATION SHOCK; HELIOSPHERIC RADIO EMISSIONS; GALACTIC COSMIC-RAY MEDIATION; INTERSTELLAR GAS; FLOW DOWNSTREAM)

**Cited References:**

\*BUR CENS, 1990, CENSUS US POPULATION  
 \*BUR CENS, 1940, 16 CENSUS US 1940 PO  
 \*NCRPM, 1987, 94 NCRPM NCRP  
 ARCHER VE, 1979, V109, P88, AM J EPIDEMIOL  
 BARLOW JS, 1962, P123, RESPONSE NERVOUS SYS  
 BEER J, 1990, V347, P164, NATURE  
 BEER J, 1994, P291, SUN VARIABLE STAR SO  
 BEIR V, 1990, HLTH EFFECTS EXPOSUR  
 BERGER A, 1990, V330, P529, PHILOS T ROY SOC A  
 CHIANG CL, 1984, LIFE ITS APPL  
 CHIE WC, 1995, V15, P511, ANTICANCER RES  
 CHO LJ, 1970, DIFFERENTIAL CURRENT  
 CLAYTON D, 1987, V6, P449, STAT MED  
 CLAYTON D, 1987, V6, P469, STAT MED  
 CURRIE RG, 1981, V86, P11055, J GEOPHYS RES  
 DIMITROV BD, 1993, V37, P68, INT J BIOMETEOROL  
 DUNCAN SR, 1992, V158, P293, J THEOR BIOL  
 DURANTE M, 1995, V34, P195, RADIAT ENVIRON BIOPH  
 ERTEL S, 1994, V81, P308, NATURWISSENSCHAFTEN  
 FEYNMAN J, 1984, V89, P3023, J GEOPHYS RES  
 FULKS GJ, 1975, V80, P1701, J GEOPHYS RES  
 HAYAKAWA S, 1969, COSMIC RAY PHYSICS  
 HERMAN JR, 1980, SUN WEATHER CLIMATE  
 HOLFORD TR, 1994, V13, P23, STAT MED  
 HOUGHTON A, 1978, P759, LANCET 0408  
 HOYLE F, 1990, V343, P304, NATURE  
 JANSSON PA, 1984, DECONVOLUTION APPL S  
 JUCKETT DA, 1993, V133, P312, RADIAT RES  
 LAVECCHIA C, 1992, V28, P927, EUR J CANCER A  
 LAVECCHIA C, 1993, V29, P431, EUR J CANCER A  
 MADIGAN MP, 1995, V87, P1681, J NATL CANCER I  
 MANDL AM, 1964, P311, EFFECTS IONIZING RAD  
 MCHARGUE LR, 1991, V21, P141, REV GEOPHYS  
 MORRIS PA, 1948, V4, P251, EXPERIENTIA  
 PRASAD KN, 1984, CRC HDB RADIOBIOLOGY  
 PRESS WH, 1992, NUMERICAL RECIPES C  
 RABINER LR, 1975, THEORY APPLICATION D  
 RANDALL W, 1991, V35, P33, INT J BIOMETEOROL  
 RANDALL W, 1993, V37, P72, INT J BIOMETEOROL  
 RUSSELL CT, 1987, P73, SOLAR WIND EARTH  
 RUSSELL WL, 1977, V74, P3523, P NATL ACAD SCI USA  
 SAKURAI K, 1987, P39, SOLAR WIND EARTH  
 SCHAEFER HJ, 1958, V9, P59, RADIAT RES  
 SCHOVE DJ, 1983, SUNSPOT CYCLES  
 SEARLE AG, 1974, V24, P171, MUTAT RES  
 SMITH CR, 1985, MAXIMUM ENTROPY BAYE

STEARNS SD, 1988, SIGNAL PROCESSING AL  
STUIVER M, 1989, V338, P405, NATURE  
STURGEON SR, 1995, V87, P1846, J NATL CANCER I  
SUESS ST, 1990, V28, P97, REV GEOPHYS  
TARONE RE, 1992, V84, P1402, J NATL CANCER I  
WALDMEIER M, 1961, SUNSPOT ACTIVITY YEA  
WELCH PD, 1967, V15, P70, IEEE T AUDIO ELECTRO  
WESLEY JP, 1960, V2, P97, INT J RADIAT BIOL  
ZHANG YQ, 1993, V34, P240, J RADIAT RES

**Abstract:** ...analysis were used to explore the hypothesis that cosmic radiation can induce germ cell changes leading to increases in future breast cancer mortality. A birth **cohort time** series for female breast cancer mortality was obtained using a model-independent, age-period-cohort analysis on age-specific mortality data for 1940-1990. The...

**Identifiers--**

---

3/5,K/20 (Item 20 from file: 34)  
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.

06818809 **Genuine Article#:** ZU623 **Number of References:** 24

**Evaluation of mortality factors and risk analysis for the design of an integrated pest management system**

**Author:** Roux O (REPRINT) ; Baumgartner J

**Corporate Source:** SWISS FED OFF AGR,MATTENHOFSTR 5/CH-3003 BERN//SWITZERLAND/  
(REPRINT); INT POTATO CTR,/ARIANA 2080//TUNISIA/; INST CTR INSECT PHYSIOL &  
ECOL,/NAIROBI//KENYA/

**Journal:** ECOLOGICAL MODELLING , 1998 , V 109 , N1 ( JUN 1 ) , P 61-75

**ISSN:** 0304-3800 **Publication date:** 19980601

**Publisher:** ELSEVIER SCIENCE BV , PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** SWITZERLAND; TUNISIA; KENYA

**Subfile:** CC AGRI--Current Contents, Agriculture, Biology & Environmental Sciences

**Journal Subject Category:** ECOLOGY

**Abstract:** A probabilistic approach of survival analysis based on the theory of competing risks was applied to the potato tuber moth *Phthorimaea operculella* (Zeller) affecting tubers in Tunisian rustic stores. Exponential curve of death, i.e. constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors, which permits to judge different control strategies. In an integrated pest management perspective, the effect of basic mortalities: i.e innate and dispersal related mortalities is recombined with native natural enemies. Thereafter, we calculate the force of additional compatible control factors needed to reduce the proportion of infested tubers below an economically relevant level. Control strategies based on native natural enemies are shown to have variable effects which put farmers at economic risks. The general importance of integrating compatible control factors is recognized in the

evaluation of virus applications. Based on risk analyses, Tunisian potato growers were recommended, in the case of standard initial infestations of five eggs per tuber, to use virus preparations at a higher dosage than the 0.0015 larval equivalent/kg as used in this study. Moreover, the study confirms the general importance of entering potatoes with low infestation levels into rustic shelters. This considerably decreases the risk of exceeding the economic threshold and make virus based control efficient even at low dosages. If the initial infestation considerably exceeds five eggs per tuber, the integration of a compatible control factor becomes more difficult. Nevertheless, even in absence of additional control factors the infestation of tubers does not exceed 50%. (C) 1998 Elsevier Science B.V. All rights reserved.

**Descriptors--**Author Keywords: survival analysis ; hazard rate functions ; competing risks

**Identifiers--** KeyWord Plus(R): PHTHORIMAEA-OPERCULELLA ZELLER; POTATO TUBERMOTH; TUNISIA

**Cited References:**

DAVID HA, 1978, V39, GRIFFINS STAT MONOGR  
 DEBACH P, 1964, BIOL CONTROL INSECT  
 ELANDTJOHNSON RC, 1980, SURVIVAL MODELS DATA  
 ESSAMET M, 1988, V61, P1, ANN I NAT RECH AGRON  
 FLINT ML, 1981, INTRO INTEGRATED PES  
 FUGLIE K, 1993, V14, P501, INSECT SCI APPL  
 HEADLEY JC, 1994, V40, P4, AM ENTOMOL  
 HEADLEY JC, 1975, P75, INTRO INSECT PEST MA  
 LAW AM, 1982, SIMULATION MODELING  
 LUCK RF, 1988, V33, P367, ANNU REV ENTOMOL  
 METCALF RL, 1975, INTRO INSECT PEST MA  
 NACHMAN G, 1984, V21, P903, J APPL ECOL  
 NAMBOODIRI NK, 1991, DEMOGRAPHIC ANAL STO  
 NAMBOODIRI NK, 1987, LFIE TABLE TECHNIQUE  
 PAPOULIS A, 1984, PROBABILITY RANDOM V  
 ROSSING WAH, 1993, DAMAGE UNCERTAINTY R  
 ROUX O, 1995, V27, P123, B ZOOL AGR BACHIC 2  
 ROUX O, 1992, V85, P2246, J ECON ENTOMOL  
 ROUX O, 1993, THESIS ETH ZURICH  
 SOUTHWOOD TRE, 1978, ECOLOGICAL METHODS  
 STERN VM, 1959, V29, P81, HILGARDIA  
 VONARX R, 1990, V31, P277, AGR ECOSYST ENVIRON  
 VONARX R, 1990, V35, P151, ENTOMOPHAGA  
 VONARX R, 1988, MANAGMENT POTATO TUB

**Abstract:** ...affecting tubers in Tunisian rustic stores. Exponential curve of death, i.e. constant force of mortality functions were used in a case study on a **cohort time** basis. The additive property of crude cause-specific forces of mortality is used to combine mortality factors, which permits to judge different control strategies. In...

**Identifiers--**

09930046 **Genuine Article#:** 465NE **Number of References:** 54

**Effect of chiropractic intervention on small scoliotic curves in younger subjects: A time-series cohort design**

**Author:** Lantz CA (REPRINT) ; Chen J

**Corporate Source:** Life Chiropract Coll W,2005 Via Barrett/San Lorenzo//CA/94580 (REPRINT); Life Chiropract Coll W,San Lorenzo//CA/94580; Life Univ,Marietta//GA/; Oregon Hlth Sci Univ,Sch Med,Portland//OR/97201

**Journal:** JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS , 2001 , V 24 , N6 ( JUL-AUG ) , P 385-393

**ISSN:** 0161-4754 **Publication date:** 20010700

**Publisher:** MOSBY, INC , 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA

**Journal Subject Category:** HEALTH CARE SCIENCES & SERVICES; INTEGRATIVE & COMPLEMENTARY MEDICINE; REHABILITATION

**Abstract:** Background: Chiropractors have long claimed to affect scoliotic curves, and case studies abound reporting on successful outcomes. No clinical trials exist, however, that evaluate chiropractic's effectiveness in the management of scoliotic curves.

**Objective:** To assess the effectiveness of chiropractic intervention in the management of adolescent idiopathic scoliosists in curves less than 20 degrees

**Design:** **Cohort time-series** trial with all subjects electing chiropractic care. Entry-level Cobb angle was compared with postmanagement curve.

**Methods:** Forty-two subjects completed the program of chiropractic intervention. Age range at entry was 6 to 12 years, and patients were included if their entry-level x-ray films revealed curves of 6 degrees to 20 degrees. Participants had adjustments performed for 1 year before followup. Full-spine osseous adjustments were the major form of intervention, but heel lifts and postural and lifestyle counseling were used as well.

**Results:** There was no discernable effect on the severity of the curves as a function of age, inial curve severity, frequency of care, or attending

**Conclusion:** Full-spine chiropractic adjustments with heel lifts and postural and lifestyle counseling are not effective in reducing the severity of scoliotic curves.

**Descriptors--** Author Keywords: scoliosis ; chiropractic manipulation ; Cobb angle

**Identifiers--** KeyWord Plus(R): IDIOPATHIC SCOLIOSIS; ADOLESCENT FEMALE; FUSION

**Cited References:**

ARAGONA R, 1986, P12, AM CHIRO

ARTHUR BE, 1986, V34, P46, EUR J CHIRO S

ASPERGREN DD, 1987, V10, P147, J MANIP PHYSIOL THER

ASPERGREN DD, 1986, V9, P230, J MANIP PHYSIOL THER  
 BARGE FH, 1986, SCOLIOSIS IDENTIFIAB  
 BARRACK RL, 1984, V9, P681, SPINE  
 BERGMANN TF, 1993, V5, P53, CHIRO TECH  
 BETGE G, 1985, V33, P71, EUR J CHIRO  
 BLOUNT WP, 1981, V63, P335, J BONE JOINT SURG AM  
 BOSLER J, 1979, V1, P95, MED J AUSTRALIA  
 BRADFORD DS, 1988, V229, P70, CLIN ORTHOPAEDICS  
 BROOKS HL, 1975, V57, P968, J BONE JOINT SURG AM  
 BUNNELL WP, 1979, V10, P813, ORTHOP CLIN N AM  
 COILLARD C, 1999, V53, P781, ANN CHIR  
 COX JM, 1986, P45, ACA J CHIROP  
 DAHER YH, 1985, V10, P609, SPINE  
 DANBERT RJ, 1970, V12, P38, J MANIP PHYSIOL THER  
 DELAHUERTA E, 1998, V52, P776, ANN CHIR  
 DESMET AA, 1982, V64, P489, J BONE JOINT SURG AM  
 DICKSON RA, 1985, V67, P176, J BONE JOINT SURG BR  
 DUVALBEAUPERE G, 1985, V10, P428, SPINE  
 ERIKSEN K, 1996, V3, P25, CHIRO RES J  
 FERGUSON RL, 1988, V19, P419, ORTHOP CLIN N AM  
 FOWLES JV, 1978, V134, P212, CLIN ORTHOPAEDICS  
 HILDEBRANDT RW, 1986, V9, P181, J MANIP PHYSIOL THER  
 INGLIS B, 1979, NZ GOVT PRINTER  
 KAHANOVITZ N, 1989, V14, P483, SPINE  
 KAHANOVITZ N, 1986, V11, P753, SPINE  
 KOSTUIK JP, 1988, V19, P371, ORTHOP CLIN N AM  
 LAWRENCE DJ, 1987, V10, P334, J MANIP PHYSIOL THER  
 LONSTEIN JE, 1984, V66, P1061, J BONE JOINT SURG AM  
 MACLEAN WE, 1989, V9, P257, J PEDIATR ORTHOPED  
 MADIGAN RR, 1983, V76, P292, J TENNESSEE MED ASS  
 MAHER D, 1986, V9, P231, J MANIP PHYSIOL THER  
 MAWHINEY RB, 1982, SCOLIOSIS MANUAL  
 MAWHINEY RB, 1982, P210, DIGEST CHIRO EC  
 MAWHINEY RB, 1989, CLIN REPORT REDUCTIO  
 MAWHINEY RB, 1984, P65, DIGEST CHIRO EC  
 MORIAS T, 1985, V75, P1377, AM J PUBLIC HEALTH  
 NYKOLIATION JW, 1986, V9, P1, J MANIP PHYSIOL THER  
 PICETTI G, 1998, V21, P1285, ORTHOPEDICS  
 PLAUGHER G, 1990, V13, P498, J MANIP PHYSIOL THER  
 POSSIN DM, 1989, V2, P99, CHIROPRACTIC  
 RANZIEN R, 1987, V10, P130, J MANIP PHYSIOL THER  
 SALLAHIAN CA, 1991, V7, P42, J CHIRO RES CLIN INV  
 SCHOMMER N, 1987, STOPPING SCOLIOSIS  
 STEVENS RF, 1983, V17, P72, ACA J CHIRO  
 SULLIVAN EC, 1987, V10, P333, J MANIP PHYSIOL THER  
 SWANK SM, 1979, V10, P891, ORTHOP CLIN N AM



TOLO VT, 1983, V8, P373, SPINE  
TORELL G, 1981, V63, P337, J BONE JOINT SURG AM  
WICKERS FC, 1977, V10, P790, SPINE  
WINTER RB, 1975, V57, P972, J BONE JOINT SURG AM  
WYNNE EJ, 1984, V75, P277, CAN J PUBLIC HLTH  
**Abstract:** ...of scoliotic curves.

**Objective:** To assess the effectiveness of chiropractic intervention in the management of adolescent idiopathic scolios in curves less than 20 degrees

**Design:** **Cohort time-series** trial with all subjects electing chiropractic care. Entry-level Cobb angle was compared with postmanagement curve.

**Methods:** Forty-two subjects completed the program of...

**Identifiers--**

---

3/5,K/6 (Item 6 from file: 34)  
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
(c) 2009 The Thomson Corp. All rights reserved.

10977001 **Genuine Article#:** 591RP **Number of References:** 15

**A single cohort time delay model of the life-cycle of the salmon louse *Lepeophtheirus salmonis* on Atlantic salmon *Salmo salar***

**Author:** Tucker CS; Norman R (REPRINT) ; Shinn AP; Bron JE; Sommerville C; Wootten R  
**Corporate Source:** Univ Stirling,Dept Math & Comp Sci,Stirling FK9 4LA//Scotland/ (REPRINT);  
Univ Stirling,Dept Math & Comp Sci,Stirling FK9 4LA//Scotland/; Univ Stirling,Inst  
Aquaculture,Stirling FK9 4LA//Scotland/

**Journal:** FISH PATHOLOGY , 2002 , V 37 , N3 ( SEP ) , P 107-118

**ISSN:** 0388-788X **Publication date:** 20020900

**Publisher:** JAPAN SOC FISH PATHOL DEPT FISHERIES-FAC AGR , UNIV TOKYO YAY01 1-1-  
1 BUNKYO-KU, TOKYO, 113, JAPAN

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** Scotland

**Journal Subject Category:** FISHERIES; VETERINARY SCIENCES

**Abstract:** A single **cohort time** delay differential equation model of *Lepeophtheirus salmonis* population dynamics was developed. The model was parameterised using data from tank infection trials, which followed a single experimental cohort of post-settlement lice through all the developmental stages. This simple mathematical model successfully predicted the timing and numbers of parasites present on the host. However, the death rates of parasitic louse stages within the tank trials were found to be highly variable despite the simplified conditions prevailing within such a system. Embryonic development, free-living nauplius stages and infection parameters were added to this model to allow the complete parasite life-cycle to be described. In addition simulations were carried out to determine the effect upon short-term salmon louse population dynamics of employing a notional chemotherapeutant having an arbitrary instantaneous efficacy of 80%. These results were used to determine the optimal

timing of treatment relative to initial lice counts. This was found to be different for male and female lice stages, reflecting their respective developmental rates.

**Descriptors--** Author Keywords: *Lepeophtheirus salmonis* ; epidemiological model ; epidemiology ; population dynamics ; *Salmo salar*

**Identifiers--** KeyWord Plus(R): CALIGIDAE; COPEPODA; SETTLEMENT; SURVIVAL; KROYER; GROWTH

**Cited References:**

ANSTENSRUD M, 1990, V70, P269, J MAR BIOL ASSOC UK  
BENCE J, 1986, SOLVER ADAPTABLE PRO  
BRON JE, 1993, P263, PATHOGENS WILD FARME  
JOHNSON SC, 1991, V69, P929, CAN J ZOOL  
JOHNSON SC, 1991, V71, P425, J MAR BIOL ASSOC UK  
KABATA Z, 1979, PARASITIC COPEPODA B  
PIKE AW, 1999, V44, P233, ADV PARASIT  
RAE GH, 1999, V3, P46, FISH VET J  
TUCKER CS, 2000, V23, P309, J FISH DIS  
TUCKER CS, 2002, V49, P145, DIS AQUAT ORGAN  
TUCKER CS, 1998, THESIS U STIRLING ST  
TUCKER CS, 2000, V35, P137, FISH PATHOL  
TULLY O, 1989, V69, P279, J MAR BIOL ASSOC UK  
WADSWORTH S, 1998, V21, P8, FISH FARMER  
WOOTEN R, 1982, V81, P185, P ROY SOC EDINB B

**A single cohort time delay model of the life-cycle of the salmon louse *Lepeophtheirus salmonis* on Atlantic salmon *Salmo salar***

**Abstract:** A single cohort time delay differential equation model of *Lepeophtheirus salmonis* population dynamics was developed. The model was parameterised using data from tank infection trials, which followed a single...

**Identifiers--**

15/5,K/40 (Item 28 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

08251247 **Genuine Article#:** 262VY **Number of References:** 30

**Is carotid endarterectomy cost-effective in symptomatic patients with moderate (50% to 69%) stenosis?**

**Author:** Patel ST; Haser PB; Korn P; Bush HL; Deitch JS; Kent KC (REPRINT)

**Corporate Source:** CORNELL UNIV,WEILL MED COLL, NEW YORK PRESBYTERIAN HOSP, DIV VASC SURG, 525 E 68TH ST, R/NEW YORK//NY/10021 (REPRINT); CORNELL UNIV,WEILL MED COLL, NEW YORK PRESBYTERIAN HOSP, DIV VASC SURG/NEW YORK//NY/10021

**Journal:** JOURNAL OF VASCULAR SURGERY , 1999 , V 30 , N6 ( DEC ) , P 1024-1032

**ISSN:** 0741-5214 **Publication date:** 19991200

**Publisher:** MOSBY-YEAR BOOK INC , 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO

63146-3318

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA

**Subfile:** CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine

**Journal Subject Category:** SURGERY; PERIPHERAL VASCULAR DISEASE

**Abstract:** Objective: Recently published data from the North American Carotid Endarterectomy Trial revealed a benefit for carotid endarterectomy (CEA) in symptomatic patients with moderate (50% to 69%) carotid stenosis. This benefit was significant but small (absolute stroke risk reduction at 5 years, 6.5%; 22.2% vs 15.7%), and thus, the authors of this study were tentative in the recommendation of operation for these patients. To better elucidate whether CEA in symptomatic **patients** with moderate carotid stenosis is a proper **allocation** of societal **resources**, we examined the cost-**effectiveness** of this **intervention**.

**Methods:** A decision-analytic Markov process model was constructed to determine the cost-effectiveness of CEA versus medical treatment for a hypothetical cohort: of 66-year-old patients with moderate: carotid stenosis. This model allowed the comparison of not only the immediate hospitalization but also the lifetime costs and benefits of these two strategies. Our measure of outcome was the cost-effectiveness ratio (CER), defined as the incremental lifetime cost per quality-adjusted life year saved. We assumed an operative stroke and death rate of 6.6% and a declining risk of ipsilateral stroke after the ischemic event with medical treatment (first year, 9.3%; second year, 4%; subsequent years, 3%). The hospitalization cost of CEA (\$6420) and the annual costs of major stroke (\$26,880), minor stroke (\$798), and aspirin therapy (\$63) were estimated from a hospital cost accounting system and the literature.

**Results:** CEA for moderate carotid stenosis increased the survival rate by 0.13 quality-adjusted life years as compared with medical treatment at an additional lifetime cost: of \$580. Thus, CEA was cost-effective with a CER of \$4462. Society is usually willing to pay for interventions with CERs of less than \$60,000 leg, CERs for coronary artery bypass grafting at \$9100 and for dialysis at \$53,000). CEA was not cost-effective if the perioperative risk was greater than 11.3%, if the ipsilateral stroke rate associated with medical treatment at 1 year was reduced to 4.3%, if the age of the patient exceeded 83 years, or if the cost of CEA exceeded \$13,200.

**Conclusion:** CEA in patients with symptomatic moderate carotid stenosis of 50% to 69% is cost-effective. Perioperative: risk of stroke or death, medical and surgical stroke risk, cost of CEA, and age are important determinants of the cost-effectiveness of this intervention.

**Identifiers--** KeyWord Plus(R): STROKE; SURGERY; OPERATIONS; COMMUNITY; RISKS

**Cited References:**

- \*EUR CAR SURG TRIA, 1998, V351, P1379, LANCET
- \*EUR CAR SURG TRIA, 1991, V337, P1235, LANCET
- \*EX COMM ASYMPT CA, 1995, V273, P1421, JAMA-J AM MED ASSOC
- \*N AM SYMPT CAR EN, 1991, V325, P443, NEW ENGL J MED
- \*NAT CTR HLTH STAT, 1990, V2, VIT STAT US 1988
- BACK MR, 1997, V26, P456, J VASC SURG
- BARNETT HJM, 1998, V339, P1415, NEW ENGL J MED
- BAUM HM, 1981, V12, P59, STROKE S1
- BRODERICK J, 1998, V29, P415, STROKE

CRONENWETT JL, 1997, V25, P298, J VASC SURG  
 FISHER ES, 1989, V79, P1617, AM J PUBLIC HEALTH  
 GOLD MR, 1996, COST EFFECTIVENESS H  
 GOLDMAN L, 1992, V85, P1960, CIRCULATION  
 HSIA DC, 1998, V29, P346, STROKE  
 KATZ DA, 1994, V19, P980, J VASC SURG  
 KRAISS LW, 1995, V169, P512, AM J SURG  
 KUCEY DS, 1998, V28, P1051, J VASC SURG  
 KUNTZ KM, 1996, V94, P94, CIRCULATION S2  
 MATTOS MA, 1995, V21, P719, J VASC SURG  
 MAYBERG MR, 1991, V266, P3289, JAMA-J AM MED ASSOC  
 NORRIS JW, 1991, V22, P1485, STROKE  
 OSTER G, 1994, V25, P1149, STROKE  
 RODDY SP, 1998, V27, P1066, J VASC SURG  
 ROTHWELL PM, 1996, V27, P260, STROKE  
 RUBIN JR, 1988, V7, P256, J VASC SURG  
 SOLOMON NA, 1994, V25, P1721, STROKE  
 SONNENBERG FA, 1993, V13, P322, MED DECIS MAKING  
 STANGE PV, 1978, V298, P372, NEW ENGL J MED  
 WEINSTEIN MC, 1982, V66, P56, CIRCULATION S3  
 YATES GN, 1997, V173, P342, AM J SURG

**Abstract:** ...7%), and thus, the authors of this study were tentative in the recommendation of operation for these patients. To better elucidate whether CEA in symptomatic **patients** with moderate carotid stenosis is a proper **allocation** of societal **resources**, we examined the cost-**effectiveness** of this **intervention**.

Methods: A decision-analytic Markov process model was constructed to determine the cost-effectiveness of CEA versus medical treatment for a hypothetical cohort: of 66...

**Identifiers--**

15/5,K/18 (Item 6 from file: 34)  
 DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
 (c) 2009 The Thomson Corp. All rights reserved.

11179389 **Genuine Article#:** 619VZ **Number of References:** 27

**Implications of farm-level response to seasonal climate forecasts for aggregate grain production in Zimbabwe**

**Author:** Phillips JG (REPRINT) ; Deane D; Unganai L; Chimeli A

**Corporate Source:** Bard Coll,Bard Ctr Environm Policy,Annandale on Hudson//NY/12504 (REPRINT); Int Res Inst Climate Predict,Palisades//NY/; Univ London London Sch Econ & Polit Sci,London WC2A 2AE//England/; Zimbabwe Natl Meteorol Serv,Harare//Zimbabwe/

**Journal:** AGRICULTURAL SYSTEMS , 2002 , V 74 , N3 ( DEC ) , P 351-369

**ISSN:** 0308-521X **Publication date:** 20021200

**Publisher:** ELSEVIER SCI LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON,

OXFORD OX5 1GB, OXON, ENGLAND

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA; England; Zimbabwe

**Journal Subject Category:** AGRICULTURE, MULTIDISCIPLINARY

**Abstract:** Seasonal climate forecasts are now being routinely released in Zimbabwe and elsewhere, with the expectation that this information will improve crop and **resource management**. Most studies focus on the household as the **unit of analysis**, with **interventions** designed to **benefit** production risk management at the household level. Here we investigate the implications in aggregate of a widespread response to climate forecast information using the case of Zimbabwe in the 1997/1998 El Nino event and the following year's La Nina, assuming that changes in observed area planted in those two seasons can be used as a guide to potential responses to forecast information. Data from the Zimbabwe National Early Warning crop statistics database and household level surveys were used in the analysis. In the 1997/1998 El Nino year, when the official forecast for a poor rainy season was broadly disseminated, decreases in area planted were observed, but in the following year when La Nina conditions and traditional indicators portended higher than average rainfall, area planted per household rose, particularly in the driest zone. Applying observed changes in area planted and crop mix to yields over the preceding 15 seasons, we show that the impact of a forecast of drought conditions could potentially decrease production below that which would result from behavior without a forecast, but production could potentially increase in years when the forecast is for greater than average rainfall. Since production increases in favorable years would be greater in magnitude than the potential decreases in poor rainfall years, long-term mean production could increase in the presence of forecasts. However, production volatility is also shown to increase. We suggest that, if forecast information is widely disseminated and adopted in the future, appropriate market or policy interventions may need to accompany the information to optimize societal benefit of climate forecasts. (C) 2002 Elsevier Science Ltd. All rights reserved.

**Identifiers--** KeyWord Plus(R): SOUTHERN OSCILLATION; AGRICULTURE; BENEFITS

**Cited References:**

---

**USPTO Full Text Retrieval Options**

15/5,K/23 (Item 11 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

10785959 **Genuine Article#:** 570GU **Number of References:** 28

**A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker**

**Author:** Dollar A; Brown C; Putnam D; McLaughlin T (REPRINT) ; Okamoto L; Arocho R

**Corporate Source:** Cardiol Georgia,Atlanta//GA/ (REPRINT); Cardiol Georgia,Atlanta//GA/; Capital Cardiol Assoc,Albany//NY/; NDC Hlth Informat Sci,Phoenix//AZ/; Pfizer Inc,New York//NY/

**Journal:** CLINICAL THERAPEUTICS , 2002 , V 24 , N6 ( JUN ) , P 930-941

**ISSN:** 0149-2918 **Publication date:** 20020600

**Publisher:** EXCERPTA MEDICA INC , 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA

**Journal Subject Category:** PHARMACOLOGY & PHARMACY

**Abstract:** Background: Despite the high **costs** of **managing** hypertension, pharmacologic **intervention** is **cost-effective**, particularly in **patients** at highest risk for cardiovascular events. The prevalence of hypertension in the elderly and the age-associated risks of coronary artery disease and stroke suggest that early identification and aggressive treatment should be priorities in this population.

**Objective:** The aim of this study was to compare the effect of amlodipine and angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in the treatment of essential hypertension in elderly patients (>60 years) in an actual practice setting.

**Methods:** This was a retrospective cohort analysis using electronic medical records stored in the Physicians Data Corporation cardiology database. Patients aged >60 years who received care from a cardiologist and who had a recorded diagnosis of hypertension during 1997 or 1998 were identified. For inclusion, patients had to have received an initial prescription for amlodipine, an ACE inhibitor, or an ARB at the index visit. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) readings from the index visit and greater than or equal to 1 subsequent visit (<180 days after the index visit) were assessed.

**Results:** A total of 192 patients (56.3% male; mean age, 71.9 years) met the inclusion criteria. Amlodipine-treated patients experienced a mean decrease in SBP of 26.7 mm Hg, compared with 18.8 mm Hg in patients receiving an ARB and 15.8 mm Hg for patients receiving an ACE inhibitor ( $P = 0.008$ , amlodipine vs ACE inhibitor). DBP decreased 8.8 mm Hg with amlodipine, 8.7 mm Hg with an ARB, and 6.2 mm Hg with an ACE inhibitor. After adjusting for age, sex, and disease severity, amlodipine-treated patients were similar to 4 times as likely to move to a better blood pressure stage than patients treated with an ARB or an ACE inhibitor (odds ratio, ARB vs amlodipine: 0.245; 95% CI, 0.080-0.753; odds ratio, ACE inhibitor vs amlodipine: 0.234; 95% CI, 0.072-0.761).

**Conclusion:** Results of this study indicate that in patients aged >60 years, amlodipine may be an effective therapy for hypertension.

**Descriptors--** Author Keywords: hypertension ; amlodipine ; angiotensin II ; angiotensin-converting enzyme inhibitors ; antihypertensive agents

**Identifiers--** KeyWord Plus(R): ISOLATED SYSTOLIC HYPERTENSION; CORONARY HEART-DISEASE; UNITED-STATES; CALCIUM-ANTAGONISTS; ACTIVE TREATMENT; TRIALS; DETERMINANTS; MANAGEMENT; MORTALITY; MORBIDITY

**Cited References:**

- \*JOINT NAT COMM PR, 1997, V157, P2413, ARCH INTERN MED
- \*MRC WORK PART, 1992, V304, P405, BRIT MED J
- \*NIH, 1993, NIH PUBL
- \*SAS I INC, 1998, SAS PROD GUID VERS 7
- \*SHEP COOP RES GRO, 1991, V265, P3255, JAMA-J AM MED ASSOC
- AMERY A, 1985, V1, P1349, LANCET
- BLACKWELL CS, 1972, V1, P1, VIBRATIONAL SPECTRA
- BURSZTYN M, 1997, V134, P238, AM HEART J 1
- COLLINS R, 1990, V335, P827, LANCET

CORNONIHUNTLEY J, 1989, V149, P780, ARCH INTERN MED  
 DAHLOF B, 1991, V338, P1281, LANCET  
 DANNENBERG AL, 1998, V78, P676, AM J PUBLIC HEALTH  
 KELLEHER C, 2000, V7, P22, ADV RENAL REPLACE TH  
 LIU LS, 1998, V16, P1823, J HYPERTENS 1  
 MACMAHON S, 1993, V4, P265, J VASC MED BIOL  
 MANOLIO TA, 1995, V155, P829, ARCH INTERN MED  
 MCMURRAY J, 1999, V19, PS99, AM J HYPERTENS  
 NEAL B, 2000, V356, P1955, LANCET  
 NEATON JD, 1992, V152, P56, ARCH INTERN MED  
 PAHOR M, 2000, V356, P1949, LANCET  
 PARDELL H, 2000, V59, P13, DRUGS S2  
 SESSO HD, 2000, V36, P801, HYPERTENSION  
 SOMES GW, 1999, V159, P2004, ARCH INTERN MED  
 STAESSEN JA, 1997, V350, P757, LANCET  
 STAMLER J, 1993, V153, P598, ARCH INTERN MED  
 SYVANNE M, 2001, V12, P99, CORONARY ARTERY DIS  
 TEGOS TJ, 2000, V51, P793, ANGIOLOGY  
 WILKING SVB, 1988, V260, P3451, JAMA-J AM MED ASSOC

**Abstract:** Background: Despite the high **costs** of **managing** hypertension, pharmacologic **intervention** is **cost-effective**, particularly in **patients** at highest risk for cardiovascular events. The prevalence of hypertension in the elderly and the age-associated risks of coronary artery disease and stroke suggest...

**Identifiers--**

---

15/5,K/34 (Item 22 from file: 34)  
 DIALOG(R)File 34: SciSearch(R) Cited Ref Sci  
 (c) 2009 The Thomson Corp. All rights reserved.

08462182 **Genuine Article#:** 288CT **Number of References:** 18  
**Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer**

**Author:** LevyPiedbois C; DurandZaleski I (REPRINT) ; Juhel H; Schmitt C; Bellanger A ; Piedbois P  
**Corporate Source:** HOP HENRI MONDOR,51 AVE DU MARECHAL DE LATTRE DE TASSIGNY/F-94010 CRETEIL//FRANCE/ (REPRINT); INST GUSTAVE ROUSSY,DEPT PUBL HLTH & INFORMAT/VILLEJUIF//FRANCE/; HOP HENRI MONDOR,APHP, DEPT ONCOL/PARIS//FRANCE/; HOP HENRI MONDOR,APHP, DEPT PUBL HLTH/PARIS//FRANCE/; HOP LA PITIE SALPETRIERE,APHP, DEPT PHARM/PARIS//FRANCE/; ARCOS,ISSY LES MOULINEAUX//FRANCE/

**Journal:** ANNALS OF ONCOLOGY , 2000 , V 11 , N2 ( FEB ) , P 157-161

**ISSN:** 0923-7534 **Publication date:** 20000200

**Publisher:** KLUWER ACADEMIC PUBL , SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** FRANCE

**Subfile:** CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine

**Journal Subject Category:** ONCOLOGY

**Abstract:** Background: It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure. In a recent trial, median survival was 10.8 months for patients treated with irinotecan, compared to 8.5 months in patients receiving infusional 5-FU. Considering the statistically significant but clinically relatively small advantage of irinotecan over 5-FU, cost effectiveness should also be part of treatment decision.

Purpose: To relate the **costs** of each **management** approach to overall survival in **patients** with metastatic colorectal cancer.

**Patients** and methods: The healthcare costs and medical **benefits** (**treatment**-added survival) of second-line chemotherapy in patients (infusional 5-FU: 129, irinotecan: 127) were compared. Data on overall survival were drawn from a multicenter randomised trial that compared infusional 5-FU (continuous infusion, AIO, or LV5-FU2 regimens) to irinotecan alone. Costs were derived from the accounting system in two university hospitals in Paris, France.

Results: The range in total healthcare costs was 14,135 to 12,192 US\$ patient between management approaches, with irinotecan chemotherapy costing most and 5-FU-continuous infusion least. If survival was included as a treatment benefit, the cost-effectiveness ratio of irinotecan over 5-FU ranged from 9,344 to 10,137 US\$ per year of added survival.

Conclusions: The least expensive management for metastatic colorectal was 5-FU infusion but the additional cost of irinotecan was balanced by the added months of survival, with a cost-effectiveness ratio close to that of other cancer treatments.

**Descriptors--** Author Keywords: 5-fluorouracil ; chemotherapy ; colorectal cancer ; cost/effectiveness analysis ; irinotecan

**Identifiers--** KeyWord Plus(R): RANDOMIZED TRIAL; FLUOROURACIL; CARCINOMA; ONCOLOGY; BOLUS

**Cited References:**

- \*ADV COL CANC MET, 1992, V10, P896, J CLIN ONCOL
- \*ADV COL CANC MET, 1994, V12, P960, J CLIN ONCOL
- \*CAN COORD OFF HLT, 1994, GUID EC EV DRUGS
- \*MET AN GROUP CANC, 1998, V16, P301, J CLIN ONCOL
- \*MET AN GROUP CANC, 1996, V88, P252, J NATL CANCER I
- \*TASK FORC PRINC E, 1995, V122, P61, ANN INTERN MED
- DEGRAMONT A, 1997, V15, P808, J CLIN ONCOL
- DOUILLARD JY, 1999, V18, P899, P AM SOC CLIN ONCOL
- DRUMMOND M, 1989, P18, METHODS EC EVALUATIO
- LAUPACIS A, 1992, V146, P473, CAN MED ASSOC J
- LOKICH JJ, 1989, V7, P425, J CLIN ONCOL
- O'CONNELL MJ, 1998, V352, P1402, LANCET
- ROUGIER P, 1998, V352, P1407, LANCET
- SMITH TJ, 1993, V85, P1460, J NATL CANCER I
- THIRION P, 1998, V17, P1047, P AM SOC CLIN ONCOL



WEH HJ, 1994, V5, P233, ANN ONCOL

WEINSTEIN MC, 1996, V276, P1253, JAMA-J AM MED ASSOC

WILLIAMS N, 1993, V1, P830, SURG ANUS RECTUM COL

**Abstract:** ...statistically significant but clinically relatively small advantage of irinotecan over 5-FU, cost effectiveness should also be part of treatment decision.

Purpose: To relate the **costs** of each **management** approach to overall survival in **patients** with metastatic colorectal cancer.

**Patients** and methods: The healthcare costs and medical **benefits** (**treatment**-added survival) of second-line chemotherapy in patients (infusional 5-FU: 129, irinotecan: 127) were compared. Data on overall survival were drawn from a multicenter...

**Identifiers--**

---

15/5,K/45 (Item 33 from file: 34)

DIALOG(R)File 34: SciSearch(R) Cited Ref Sci

(c) 2009 The Thomson Corp. All rights reserved.

07649628 **Genuine Article#:** 191WF **Number of References:** 13

**Health-related quality of life and functional outcome following arterial reconstruction for limb salvage**

**Author:** Seabrook GR (REPRINT) ; Cambria RA; Freischlag JA; Towne JB

**Corporate Source:** MED COLL WISCONSIN,DEPT VASC SURG, DIV VASC SURG, 9200 W WISCONSIN AVE/MILWAUKEE//WI/53226 (REPRINT); VET AFFAIRS MED CTR,SURG SERV/MILWAUKEE//WI/

**Journal:** CARDIOVASCULAR SURGERY , 1999 , V 7 , N3 ( APR ) , P 279-286

**ISSN:** 0967-2109 **Publication date:** 19990400

**Publisher:** ELSEVIER SCI LTD , THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND

**Language:** English **Document Type:** ARTICLE

**Geographic Location:** USA

**Subfile:** CC CLIN--Current Contents, Clinical Medicine

**Journal Subject Category:** CARDIAC & CARDIOVASCULAR SYSTEMS; SURGERY

**Abstract:** Vascular surgery outcomes have traditionally been measured by limb salvage and graft patency, However, as health care resources are rationed, the patient's functional outcome and quality of life will require assessment. The in situ saphenous vein graft has proven successful in achieving long-term limb salvage for patients with critical ischemia, with the expectation of preserving a life-style and sense of well-being that would be lost with limb amputation. This study was conducted to measure functional capacity and quality of life in these patients. Seventy patients with successful in situ saphenous vein bypass grafts constructed for limb-threatening ischemia, followed for a mean of 45.6 months in a surveillance program with normal graft flow characteristics, were compared with a group of age and gender-matched controls with normal limb pressures and no history of vascular occlusive disease, A questionnaire was designed from standardized health status scales and administered to the

two groups to assess symptoms, health perceptions, physical functioning and life quality. When comparing the groups of revascularized and control patients, symptoms and perceptions about their health were similar. However, the revascularized patients had significantly decreased functional capacity in their ability to walk various distances (P less than or equal to 0.005), perform household tasks (P less than or equal to 0.001) and bathe (P less than or equal to 0.001). The patient group with vascular grafts functioned as well as the controls only in activities of dressing and using the toilet. Indicators of life quality that rate independence and mobility, including the ability to procure groceries (P less than or equal to 0.001), prepare meals (P less than or equal to 0.005) participate in social activities (P less than or equal to 0.001) and drive an automobile (P less than or equal to 0.01), were also significantly limited in the patients with successful vascular reconstructions. Although achieving long-term limb salvage and graft patency, the patients in this group of successful vascular reconstructions retain functional disabilities that require significant care. Despite these physical handicaps, these patients have a remarkably similar sense of well-being and lack of somatic complaints compared with the control group. This medical outcome study identifies the functional capacity and lifetime needs for vascular **surgery patients** that will provide **useful** data for those responsible for **allocating** health care **resources**. (C) 1999 The International Society for Cardiovascular Surgery, Published by Elsevier Science Ltd. All rights reserved.

**Descriptors--**Author Keywords: health-related quality of life ; functional outcomes

**Identifiers--** KeyWord Plus(R): PRIMARY CARE; PROFILE; QUESTIONNAIRE; RELIABILITY; STANDARDS; REVISION; VALIDITY; IMPACT

**Cited References:**

BANDYK DF, 1989, V9, P286, J VASC SURG  
BERGNER M, 1981, V19, P787, MED CARE  
CHAMBERS LW, 1982, V9, P780, J RHEUMATOL  
HUNT SM, 1981, V15, P221, SOCIAL SCI MED A  
JETTE AM, 1986, V1, P143, J GEN INTERN MED  
MCHORNEY CA, 1992, V30, P253, MED CARE S  
PARKERSON GR, 1981, V19, P806, MED CARE  
RUTHERFORD RB, 1986, V4, P80, J VASC SURG  
SCHNEIDER JR, 1993, V7, P419, ANN VASC SURG  
STEWART AL, 1988, V26, P724, MED CARE  
WARE JE, 1984, ASSESSMENT QUALITY L  
WARE JE, 1987, V40, P473, J CHRON DIS  
WARE JE, 1992, V30, P473, MED CARE

**Abstract:** ...well-being and lack of somatic complaints compared with the control group, This medical outcome study identifies the functional capacity and lifetime needs for vascular **surgery patients** that will provide **useful** data for those responsible for **allocating** health care **resources**. (C) 1999 The International Society for Cardiovascular Surgery, Published by Elsevier Science Ltd. All rights reserved.

**Identifiers--**

---

**Dialog eLink:** 

15/5,K/1 (Item 1 from file: 8)

DIALOG(R)File 8: Ei Compendex(R)

(c) 2009 Elsevier Eng. Info. Inc. All rights reserved.

0013642039 **E.I. COMPENDEX No:** 1996373250210

**Proceedings of the 1995 Goddard Conference on Space Applications of Artificial Intelligence and Emerging Information Technologies**

**Issue Title:** Advanced Space Technologies for Systems Autonomy

**Conference Title:** Proceedings of the 1995 Goddard Conference on Space Applications of Artificial Intelligence and Emerging Information Technologies

**Conference Location:** Greenbelt, MD, USA **Conference Date:** 19950509-19950511

**E.I. Conference No.:** 44986

Telematics and Informatics ( Telematics Inf ) 1995 12/3-4 (141-266)

**Publication Date:** 19951201

**Publisher:** Pergamon Press Inc

**CODEN:** TEINE **ISSN:** 0736-5853

**Item Identifier (DOI):** [10.1016/0736-5853\(95\)00015-1](https://doi.org/10.1016/0736-5853(95)00015-1)

**Document Type:** Conference Review; Conference Proceeding **Record Type:** Abstract

**Treatment:** A; (Applications); T; (Theoretical)

**Language:** English **Summary Language:** English

The proceedings contains 8 papers. Topics discussed include genetic algorithms for satellite **resource allocation**, satellite-based instrument, real-time value-driven **diagnosis**, knowledge representation system, communication satellite constellations, fuzzy logic techniques, automated agent and ground control limits in autonomous spacecraft.

**Descriptors:** Communication satellites; Docking; Fuzzy sets; Genetic algorithms; Geostationary satellites; Knowledge representation; Mathematical models; Monitoring; Real time systems; Resource allocation; Space applications; Space rendezvous; \*Telecommunication

**Identifiers:** Autonomous spacecraft; EiRev; Multi-agent systems; Orbital satellite; Satellite based instrument; Satellite resource allocation

**Classification Codes:**

655.2.1 (Communication Satellites)

722.4 (Digital Computers & Systems)

723.4 (Artificial Intelligence)

921.6 (Numerical Methods)

656 (Space Flight)

716 (Electronic Equipment, Radar, Radio & Television)

The proceedings contains 8 papers. Topics discussed include genetic algorithms for satellite **resource allocation**, satellite-based instrument, real-time value-driven **diagnosis**, knowledge representation system, communication satellite constellations, fuzzy logic techniques, automated agent and ground control limits in autonomous spacecraft.

**Descriptors:**

15/5,K/2 (Item 2 from file: 8)

DIALOG(R)File 8: Ei Compendex(R)

(c) 2009 Elsevier Eng. Info. Inc. All rights reserved.

0013568506 **E.I. COMPENDEX No:** 1996193102988

## Scoping software projects

Sulgrove, Robert N.

**Corresp. Author/Affil:** Sulgrove, Robert N.

AT&T technical journal ( AT&T Tech J ) 1996 75/1 (35-45)

**Publication Date:** 19960101

**Publisher:** AT&T

**CODEN:** ATJOE **ISSN:** 8756-2324

**Document Type:** Article; Journal **Record Type:** Abstract

**Treatment:** G; (General review)

**Language:** English **Summary Language:** English

**Number of References:** 7

The key to risk management is to be as complete as possible in identifying project risks. This paper discusses the project-scoping process, which is being successfully used by software developers at AT&T Global Information Solutions. Project scoping is a method or process used for identifying and assessing risks to determine a project's feasibility. Lists of requirement categories and risk factors are provided as facilitating tools. Project scoping provides a basis for defining a less risky project and for redefining or discontinuing projects that are too risky. The project-scoping process also provides a basis for continuously monitoring risks during development to detect emerging problems at the earliest possible moment - while there is still **time** to take **effective corrective** action. Thus, project **management** can focus on **development** problems in addition to tracking schedule compliance. The bottom line is that by implementing project scoping, management has better control over a project.

**Descriptors:** Monitoring; Production control; Project management; Risk assessment; Scheduling; Strategic planning; \*Software engineering

**Identifiers:** Project feasibility; Project scoping process; Risk management; Schedule compliance

**Classification Codes:**

723.5 (Computer Applications)

912.2 (Management)

913.1 (Production Engineering)

914.1 (Accidents & Accident Prevention)

...scoping process also provides a basis for continuously monitoring risks during development to detect emerging problems at the earliest possible moment - while there is still **time** to take **effective corrective** action. Thus, project **management** can focus on **development** problems in addition to tracking schedule compliance. The bottom line is that by implementing project scoping, management has better control over a project.

**Descriptors:**

---

15/5,K/3 (Item 3 from file: 8)

DIALOG(R)File 8: Ei Compendex(R)

(c) 2009 Elsevier Eng. Info. Inc. All rights reserved.

0013124003 **E.I. COMPENDEX No:** 1994031185675

**Cost benefit analysis of a complex system with correlated failures and repairs**

Goel, L.R.; Gupta, Rakesh; Tyagi, P.K.

**Corresp. Author/Affil:** Goel, L.R.: Meerut Univ, Meerut, India

Microelectronics Reliability ( Microelectron Reliab ) 1993 33/15 (2281-2284)

**Publication Date:** 19931201

**CODEN:** MCRLA **ISSN:** 0026-2714

**Item Identifier (DOI):** [10.1016/0026-2714\(93\)90070-F](https://doi.org/10.1016/0026-2714(93)90070-F)

**Document Type:** Article; Journal **Record Type:** Abstract

**Treatment:** A; (Applications); T; (Theoretical)

**Language:** English **Summary Language:** English

**Number of References:** 4

This paper studies the cost benefit analysis of a complex system consisting of two subsystems, say A and B, connected in series. Subsystem A consists of two identical units, whereas subsystem B has only one unit. The system operates if one of the two units of subsystem A and the subsystem B are operative. Assuming a bivariate exponential density for the joint distribution of failure and repair times of the units, some reliability characteristics useful to system managers have been obtained. Explicit results have also been obtained for the case when failure and repair times are uncorrelated.

**Descriptors:** Correlation methods; Costs; Failure analysis; Probability; Repair; Systems analysis; \*Reliability theory

**Identifiers:** Bivariate exponential **distribution;** **Cost benefit** analysis; **Repair time**

**Classification Codes:**

911.1 (Cost Accounting)

913.5 (Maintenance)

922.1 (Probability Theory)

922.2 (Mathematical Statistics)

**Identifiers:** Bivariate exponential **distribution;** **Cost benefit** analysis; **Repair time**

-----  
15/5,K/9 (Item 4 from file: 6)

DIALOG(R)File 6: NTIS

(c) 2009 NTIS, Intl Cpyrgh All Rights Res. All rights reserved.

2006903 **NTIS Accession Number:** AD-A323 680/9

**Cost Offsets for Alcoholism, Drug Abuse, and Mental Health Treatment**

Miro, R. J.

Library of Congress, Washington, DC. Federal Research Div.

**Corporate Source Codes:** 000975039; 415168

Sep 94 35p

**Language:** English

**Journal Announcement:** GRAI9716

Product reproduced from digital image. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)321-8547; and email at [orders@ntis.fedworld.gov](mailto:orders@ntis.fedworld.gov). NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

**NTIS Prices:** PC A04/MF A01

**Country of Publication:** United States

This research paper reviews and analyzes the scholarly literature on cost offsets for alcoholism, drug abuse, and mental health (ADM) treatment. Two dimensions of cost offsets are considered: (1) cost offsets resulting from reduced medical utilization following timely and appropriate ADM intervention, more precisely defined as a medical offset; and (2) cost offsets resulting from long term reductions in overall health care expenditures, including the costs of ADM treatment; the latter is a total or absolute offset that may generate cost effectiveness. This paper is divided into an introduction and three major sections on cost offsets for alcoholism, mental health, and drug abuse treatment. Because of space limitations, only the most comprehensive available studies are discussed. An effort has been made to incorporate as broad and representative a sample of findings as possible, mainly by summarizing the results of previous research reviews. A variety of sources were used in the preparation of this report, including published reports and articles, books, and unpublished papers; many of which were retrieved from the collections of the National Library of Medicine, as well as from the general collections of the Library of Congress. Valuable source materials were also provided by the Substance Abuse and Mental Health Services Administration (SAMHSA).

**Descriptors:** \*Cost analysis; \*Mental health; \*Alcoholism; \***Drug** addiction; Cost **effectiveness**; **Patients**; Health care facilities; **Intervention**; Planning programming **budgeting**; Detoxification; Drug users; Psychotherapy; Counseling; Mental disorders; Drug withdrawal; Group therapy

**Identifiers:** Health insurance; NTISDODXA

**Section Headings:** 96GE (Business and Economics--General); 92B (Behavior and Society--Psychology); 57T (Medicine and Biology--Psychiatry)

**Descriptors:** \*Cost analysis; \*Mental health; \*Alcoholism; \***Drug** addiction; Cost **effectiveness**; **Patients**; Health care facilities; **Intervention**; Planning programming **budgeting**; Detoxification; Drug users; Psychotherapy; Counseling; Mental disorders; Drug withdrawal; Group therapy

**Identifiers:**

## **V. Additional Resources Searched**

No additional results of relevance found in the additional databases identified in the cover correspondence.